CN106231900A - Compound and using method thereof - Google Patents
Compound and using method thereof Download PDFInfo
- Publication number
- CN106231900A CN106231900A CN201580020934.4A CN201580020934A CN106231900A CN 106231900 A CN106231900 A CN 106231900A CN 201580020934 A CN201580020934 A CN 201580020934A CN 106231900 A CN106231900 A CN 106231900A
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- independently
- formula
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 192
- 238000000034 method Methods 0.000 title claims abstract description 95
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 79
- 201000011510 cancer Diseases 0.000 claims abstract description 58
- 239000000203 mixture Substances 0.000 claims abstract description 58
- -1 heterocycle alkane Chemical class 0.000 claims description 99
- 230000014509 gene expression Effects 0.000 claims description 91
- 101000984015 Homo sapiens Cadherin-1 Proteins 0.000 claims description 44
- 102100025805 Cadherin-1 Human genes 0.000 claims description 43
- 102000013127 Vimentin Human genes 0.000 claims description 39
- 108010065472 Vimentin Proteins 0.000 claims description 39
- 210000005048 vimentin Anatomy 0.000 claims description 39
- 125000003118 aryl group Chemical group 0.000 claims description 29
- 102000004190 Enzymes Human genes 0.000 claims description 25
- 108090000790 Enzymes Proteins 0.000 claims description 25
- 229910052736 halogen Inorganic materials 0.000 claims description 25
- 150000002367 halogens Chemical class 0.000 claims description 24
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 24
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 21
- 239000001257 hydrogen Substances 0.000 claims description 21
- 125000001072 heteroaryl group Chemical group 0.000 claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 claims description 18
- 150000003839 salts Chemical class 0.000 claims description 17
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 229910052721 tungsten Inorganic materials 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 13
- 125000004429 atom Chemical group 0.000 claims description 12
- 239000011737 fluorine Substances 0.000 claims description 12
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 11
- 229910052731 fluorine Inorganic materials 0.000 claims description 11
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 5
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 31
- 108060008539 Transglutaminase Proteins 0.000 abstract description 21
- 102000003601 transglutaminase Human genes 0.000 abstract description 21
- 230000001629 suppression Effects 0.000 abstract description 11
- 108090000623 proteins and genes Proteins 0.000 description 89
- 239000000523 sample Substances 0.000 description 74
- 102000004169 proteins and genes Human genes 0.000 description 60
- 235000018102 proteins Nutrition 0.000 description 53
- 210000004027 cell Anatomy 0.000 description 51
- 239000002585 base Substances 0.000 description 48
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 41
- 201000010099 disease Diseases 0.000 description 40
- 239000000047 product Substances 0.000 description 40
- 108020004707 nucleic acids Proteins 0.000 description 37
- 102000039446 nucleic acids Human genes 0.000 description 37
- 150000007523 nucleic acids Chemical class 0.000 description 37
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 34
- 229910052757 nitrogen Inorganic materials 0.000 description 33
- 239000000463 material Substances 0.000 description 32
- 108010053763 Pyruvate Carboxylase Proteins 0.000 description 29
- 102100039895 Pyruvate carboxylase, mitochondrial Human genes 0.000 description 29
- 210000001519 tissue Anatomy 0.000 description 29
- 238000012360 testing method Methods 0.000 description 26
- 229940088598 enzyme Drugs 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 23
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 23
- 108090000765 processed proteins & peptides Proteins 0.000 description 23
- 230000008859 change Effects 0.000 description 22
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 239000003814 drug Substances 0.000 description 22
- 108020004999 messenger RNA Proteins 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 102000004196 processed proteins & peptides Human genes 0.000 description 21
- 229920001184 polypeptide Polymers 0.000 description 20
- 230000000694 effects Effects 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 16
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 16
- 230000008569 process Effects 0.000 description 15
- 238000003756 stirring Methods 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- 239000000872 buffer Substances 0.000 description 13
- 238000001514 detection method Methods 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 12
- 230000000875 corresponding effect Effects 0.000 description 12
- 238000002372 labelling Methods 0.000 description 12
- 239000002299 complementary DNA Substances 0.000 description 11
- 230000002255 enzymatic effect Effects 0.000 description 11
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene chloride Substances ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 208000024891 symptom Diseases 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 10
- 241001597008 Nomeidae Species 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 10
- 210000002919 epithelial cell Anatomy 0.000 description 10
- 239000012530 fluid Substances 0.000 description 10
- 230000002068 genetic effect Effects 0.000 description 10
- 125000005842 heteroatom Chemical group 0.000 description 10
- 238000012552 review Methods 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 238000013518 transcription Methods 0.000 description 10
- 230000035897 transcription Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000000460 chlorine Substances 0.000 description 9
- 125000000623 heterocyclic group Chemical group 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 238000005259 measurement Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- 238000013459 approach Methods 0.000 description 8
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Substances C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 239000007864 aqueous solution Substances 0.000 description 7
- 235000013922 glutamic acid Nutrition 0.000 description 7
- 239000004220 glutamic acid Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000013610 patient sample Substances 0.000 description 7
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000002532 enzyme inhibitor Substances 0.000 description 6
- 229940125532 enzyme inhibitor Drugs 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000009169 immunotherapy Methods 0.000 description 6
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 6
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 6
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 238000002626 targeted therapy Methods 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 125000006479 2-pyridyl methyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 239000007832 Na2SO4 Substances 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000012491 analyte Substances 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 230000001413 cellular effect Effects 0.000 description 5
- 229940127089 cytotoxic agent Drugs 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000006073 displacement reaction Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108010029645 galactitol 2-dehydrogenase Proteins 0.000 description 5
- 229930195712 glutamate Natural products 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl chloride Substances ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 229910052938 sodium sulfate Inorganic materials 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 0 C[C@]1SC*NC1* Chemical compound C[C@]1SC*NC1* 0.000 description 4
- 102000000905 Cadherin Human genes 0.000 description 4
- 108050007957 Cadherin Proteins 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 229920000858 Cyclodextrin Polymers 0.000 description 4
- 101710088194 Dehydrogenase Proteins 0.000 description 4
- 102000009127 Glutaminase Human genes 0.000 description 4
- 108010073324 Glutaminase Proteins 0.000 description 4
- VSNHCAURESNICA-UHFFFAOYSA-N Hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- PLXBWHJQWKZRKG-UHFFFAOYSA-N Resazurin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3[N+]([O-])=C21 PLXBWHJQWKZRKG-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 125000001118 alkylidene group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- NZNMSOFKMUBTKW-UHFFFAOYSA-M cyclohexanecarboxylate Chemical compound [O-]C(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-M 0.000 description 4
- 235000013601 eggs Nutrition 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000003818 flash chromatography Methods 0.000 description 4
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 4
- 229960001330 hydroxycarbamide Drugs 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 4
- 235000015097 nutrients Nutrition 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 238000003752 polymerase chain reaction Methods 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 4
- 230000008685 targeting Effects 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- HNNQYHFROJDYHQ-UHFFFAOYSA-N 3-(4-ethylcyclohexyl)propanoic acid 3-(3-ethylcyclopentyl)propanoic acid Chemical compound CCC1CCC(CCC(O)=O)C1.CCC1CCC(CCC(O)=O)CC1 HNNQYHFROJDYHQ-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 229910019213 POCl3 Inorganic materials 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Chemical compound CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 3
- 238000003149 assay kit Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 201000008275 breast carcinoma Diseases 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 239000002254 cytotoxic agent Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 125000004415 heterocyclylalkyl group Chemical group 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 210000003917 human chromosome Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- ZQWPRMPSCMSAJU-UHFFFAOYSA-N methyl cyclohexanecarboxylate Chemical compound COC(=O)C1CCCCC1 ZQWPRMPSCMSAJU-UHFFFAOYSA-N 0.000 description 3
- KRKPYFLIYNGWTE-UHFFFAOYSA-N n,o-dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 125000006574 non-aromatic ring group Chemical group 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- LETVJWLLIMJADE-UHFFFAOYSA-N pyridazin-3-amine Chemical compound NC1=CC=CN=N1 LETVJWLLIMJADE-UHFFFAOYSA-N 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 238000004809 thin layer chromatography Methods 0.000 description 3
- 229960000575 trastuzumab Drugs 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 244000050510 Cunninghamia lanceolata Species 0.000 description 2
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 108700039887 Essential Genes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 101710113864 Heat shock protein 90 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 208000034578 Multiple myelomas Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108091007960 PI3Ks Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 2
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 208000006265 Renal cell carcinoma Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- DGYIJVNZSDYBOE-UHFFFAOYSA-N [CH2]C1=CC=NC=C1 Chemical group [CH2]C1=CC=NC=C1 DGYIJVNZSDYBOE-UHFFFAOYSA-N 0.000 description 2
- 230000007488 abnormal function Effects 0.000 description 2
- ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 230000029936 alkylation Effects 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 2
- 125000002393 azetidinyl group Chemical group 0.000 description 2
- 235000019445 benzyl alcohol Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001768 cations Chemical class 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- PNZXMIKHJXIPEK-UHFFFAOYSA-N cyclohexanecarboxamide Chemical compound NC(=O)C1CCCCC1 PNZXMIKHJXIPEK-UHFFFAOYSA-N 0.000 description 2
- 210000004292 cytoskeleton Anatomy 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000003963 dichloro group Chemical group Cl* 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 229940121647 egfr inhibitor Drugs 0.000 description 2
- 150000002118 epoxides Chemical class 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 229960002949 fluorouracil Drugs 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960004891 lapatinib Drugs 0.000 description 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 210000002381 plasma Anatomy 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920001451 polypropylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000013615 primer Substances 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 239000013014 purified material Substances 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229950007866 tanespimycin Drugs 0.000 description 2
- 125000002769 thiazolinyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 2
- XPDWGBQVDMORPB-UHFFFAOYSA-N trifluoromethane acid Natural products FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- NNJPGOLRFBJNIW-HNNXBMFYSA-N (-)-demecolcine Chemical compound C1=C(OC)C(=O)C=C2[C@@H](NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-HNNXBMFYSA-N 0.000 description 1
- MWTUOSWPJOUADP-XDJHFCHBSA-N (5z)-5-(4-hydroxy-6-oxo-3-propan-2-ylcyclohexa-2,4-dien-1-ylidene)-4-(1-methylindol-5-yl)-1,2,4-triazolidin-3-one Chemical compound O=C1C=C(O)C(C(C)C)=C\C1=C\1N(C=2C=C3C=CN(C)C3=CC=2)C(=O)NN/1 MWTUOSWPJOUADP-XDJHFCHBSA-N 0.000 description 1
- FPVKHBSQESCIEP-UHFFFAOYSA-N (8S)-3-(2-deoxy-beta-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidazo[4,5-d][1,3]diazepin-8-ol Natural products C1C(O)C(CO)OC1N1C(NC=NCC2O)=C2N=C1 FPVKHBSQESCIEP-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- HJTAZXHBEBIQQX-UHFFFAOYSA-N 1,5-bis(chloromethyl)naphthalene Chemical compound C1=CC=C2C(CCl)=CC=CC2=C1CCl HJTAZXHBEBIQQX-UHFFFAOYSA-N 0.000 description 1
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-AAKVHIHISA-N 2,3-bis[[(z)-12-hydroxyoctadec-9-enoyl]oxy]propyl (z)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCC(O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(O)CCCCCC)COC(=O)CCCCCCC\C=C/CC(O)CCCCCC ZEMPKEQAKRGZGQ-AAKVHIHISA-N 0.000 description 1
- QXLQZLBNPTZMRK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-1-(2,4-dimethylphenyl)prop-2-en-1-one Chemical compound CN(C)CC(=C)C(=O)C1=CC=C(C)C=C1C QXLQZLBNPTZMRK-UHFFFAOYSA-N 0.000 description 1
- HLWOZZQVALWHFP-UHFFFAOYSA-N 2-[4-(trifluoromethoxy)phenyl]acetamide Chemical compound NC(=O)CC1=CC=C(OC(F)(F)F)C=C1 HLWOZZQVALWHFP-UHFFFAOYSA-N 0.000 description 1
- WJUNQSYQHHIVFX-UHFFFAOYSA-N 2-amino-4-[2,4-dichloro-5-(2-pyrrolidin-1-ylethoxy)phenyl]-n-ethylthieno[2,3-d]pyrimidine-6-carboxamide Chemical compound N1=C(N)N=C2SC(C(=O)NCC)=CC2=C1C(C(=CC=1Cl)Cl)=CC=1OCCN1CCCC1 WJUNQSYQHHIVFX-UHFFFAOYSA-N 0.000 description 1
- MWYDSXOGIBMAET-UHFFFAOYSA-N 2-amino-N-[7-methoxy-8-(3-morpholin-4-ylpropoxy)-2,3-dihydro-1H-imidazo[1,2-c]quinazolin-5-ylidene]pyrimidine-5-carboxamide Chemical compound NC1=NC=C(C=N1)C(=O)N=C1N=C2C(=C(C=CC2=C2N1CCN2)OCCCN1CCOCC1)OC MWYDSXOGIBMAET-UHFFFAOYSA-N 0.000 description 1
- FGEAOSXMQZWHIQ-UHFFFAOYSA-N 2-chloro-2-phenylacetyl chloride Chemical compound ClC(=O)C(Cl)C1=CC=CC=C1 FGEAOSXMQZWHIQ-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 1
- UZFPOOOQHWICKY-UHFFFAOYSA-N 3-[13-[1-[1-[8,12-bis(2-carboxyethyl)-17-(1-hydroxyethyl)-3,7,13,18-tetramethyl-21,24-dihydroporphyrin-2-yl]ethoxy]ethyl]-18-(2-carboxyethyl)-8-(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid Chemical compound N1C(C=C2C(=C(CCC(O)=O)C(C=C3C(=C(C)C(C=C4N5)=N3)CCC(O)=O)=N2)C)=C(C)C(C(C)O)=C1C=C5C(C)=C4C(C)OC(C)C1=C(N2)C=C(N3)C(C)=C(C(O)C)C3=CC(C(C)=C3CCC(O)=O)=NC3=CC(C(CCC(O)=O)=C3C)=NC3=CC2=C1C UZFPOOOQHWICKY-UHFFFAOYSA-N 0.000 description 1
- 125000006041 3-hexenyl group Chemical group 0.000 description 1
- BDCLDNALSPBWPQ-UHFFFAOYSA-N 3-oxohexanoic acid Chemical compound CCCC(=O)CC(O)=O BDCLDNALSPBWPQ-UHFFFAOYSA-N 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- ZFVRYNYOPQZKDG-UHFFFAOYSA-N 4-[6,6-dimethyl-4-oxo-3-(trifluoromethyl)-5,7-dihydroindazol-1-yl]-2-[(4-hydroxycyclohexyl)amino]benzamide Chemical compound O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C(C=1)=CC=C(C(N)=O)C=1NC1CCC(O)CC1 ZFVRYNYOPQZKDG-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- IDPUKCWIGUEADI-UHFFFAOYSA-N 5-[bis(2-chloroethyl)amino]uracil Chemical compound ClCCN(CCCl)C1=CNC(=O)NC1=O IDPUKCWIGUEADI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- WYWHKKSPHMUBEB-UHFFFAOYSA-N 6-Mercaptoguanine Natural products N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 1
- VVIAGPKUTFNRDU-UHFFFAOYSA-N 6S-folinic acid Natural products C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- SJVQHLPISAIATJ-ZDUSSCGKSA-N 8-chloro-2-phenyl-3-[(1S)-1-(7H-purin-6-ylamino)ethyl]-1-isoquinolinone Chemical compound C1([C@@H](NC=2C=3N=CNC=3N=CN=2)C)=CC2=CC=CC(Cl)=C2C(=O)N1C1=CC=CC=C1 SJVQHLPISAIATJ-ZDUSSCGKSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N 9-cis-retinoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- QULDDKSCVCJTPV-UHFFFAOYSA-N BIIB021 Chemical compound COC1=C(C)C=NC(CN2C3=NC(N)=NC(Cl)=C3N=C2)=C1C QULDDKSCVCJTPV-UHFFFAOYSA-N 0.000 description 1
- CWHUFRVAEUJCEF-UHFFFAOYSA-N BKM120 Chemical compound C1=NC(N)=CC(C(F)(F)F)=C1C1=CC(N2CCOCC2)=NC(N2CCOCC2)=N1 CWHUFRVAEUJCEF-UHFFFAOYSA-N 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VSEIDZLLWQQJGK-CHOZPQDDSA-N CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O Chemical compound CCC1=C(C)C2=N\C\1=C/C1=C(C)C(C(O)=O)=C(N1)\C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)=C1/N=C(/C=C3\N/C(=C\2)C(C=C)=C3C)[C@@H](C)[C@@H]1CCC(O)=O VSEIDZLLWQQJGK-CHOZPQDDSA-N 0.000 description 1
- FVLVBPDQNARYJU-XAHDHGMMSA-N C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O Chemical compound C[C@H]1CCC(CC1)NC(=O)N(CCCl)N=O FVLVBPDQNARYJU-XAHDHGMMSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- SHHKQEUPHAENFK-UHFFFAOYSA-N Carboquone Chemical compound O=C1C(C)=C(N2CC2)C(=O)C(C(COC(N)=O)OC)=C1N1CC1 SHHKQEUPHAENFK-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- AOCCBINRVIKJHY-UHFFFAOYSA-N Carmofur Chemical compound CCCCCCNC(=O)N1C=C(F)C(=O)NC1=O AOCCBINRVIKJHY-UHFFFAOYSA-N 0.000 description 1
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 1
- 108010031896 Cell Cycle Proteins Proteins 0.000 description 1
- 102000005483 Cell Cycle Proteins Human genes 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- PWALBVGIBABCPQ-UHFFFAOYSA-N Clc1ccc(C(CC2)CC2c(cc2)nnc2Cl)nn1 Chemical compound Clc1ccc(C(CC2)CC2c(cc2)nnc2Cl)nn1 PWALBVGIBABCPQ-UHFFFAOYSA-N 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- NNJPGOLRFBJNIW-UHFFFAOYSA-N Demecolcine Natural products C1=C(OC)C(=O)C=C2C(NC)CCC3=CC(OC)=C(OC)C(OC)=C3C2=C1 NNJPGOLRFBJNIW-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- SAMRUMKYXPVKPA-VFKOLLTISA-N Enocitabine Chemical compound O=C1N=C(NC(=O)CCCCCCCCCCCCCCCCCCCCC)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 SAMRUMKYXPVKPA-VFKOLLTISA-N 0.000 description 1
- HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- MPJKWIXIYCLVCU-UHFFFAOYSA-N Folinic acid Natural products NC1=NC2=C(N(C=O)C(CNc3ccc(cc3)C(=O)NC(CCC(=O)O)CC(=O)O)CN2)C(=O)N1 MPJKWIXIYCLVCU-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- RVAQIUULWULRNW-UHFFFAOYSA-N Ganetespib Chemical compound C1=C(O)C(C(C)C)=CC(C=2N(C(O)=NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O RVAQIUULWULRNW-UHFFFAOYSA-N 0.000 description 1
- JRZJKWGQFNTSRN-UHFFFAOYSA-N Geldanamycin Natural products C1C(C)CC(OC)C(O)C(C)C=C(C)C(OC(N)=O)C(OC)CCC=C(C)C(=O)NC2=CC(=O)C(OC)=C1C2=O JRZJKWGQFNTSRN-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000012411 Intermediate Filament Proteins Human genes 0.000 description 1
- 108010061998 Intermediate Filament Proteins Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002145 L01XE14 - Bosutinib Substances 0.000 description 1
- UIARLYUEJFELEN-LROUJFHJSA-N LSM-1231 Chemical compound C12=C3N4C5=CC=CC=C5C3=C3C(=O)NCC3=C2C2=CC=CC=C2N1[C@]1(C)[C@](CO)(O)C[C@H]4O1 UIARLYUEJFELEN-LROUJFHJSA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- LPGWZGMPDKDHEP-HLTPFJCJSA-N Leurosine Chemical compound C([C@]1([C@@H]2O1)CC)N(CCC=1C3=CC=CC=C3NC=11)C[C@H]2C[C@]1(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC LPGWZGMPDKDHEP-HLTPFJCJSA-N 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Lomustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- XOGTZOOQQBDUSI-UHFFFAOYSA-M Mesna Chemical compound [Na+].[O-]S(=O)(=O)CCS XOGTZOOQQBDUSI-UHFFFAOYSA-M 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- VFKZTMPDYBFSTM-KVTDHHQDSA-N Mitobronitol Chemical compound BrC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CBr VFKZTMPDYBFSTM-KVTDHHQDSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical compound N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 description 1
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- ZYTUAKODJSSPFK-UHFFFAOYSA-N OC(=O)C(CC=O)N1CCOCC1 Chemical compound OC(=O)C(CC=O)N1CCOCC1 ZYTUAKODJSSPFK-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- QIUASFSNWYMDFS-NILGECQDSA-N PX-866 Chemical compound CC(=O)O[C@@H]1C[C@]2(C)C(=O)CC[C@H]2C2=C1[C@@]1(C)[C@@H](COC)OC(=O)\C(=C\N(CC=C)CC=C)C1=C(O)C2=O QIUASFSNWYMDFS-NILGECQDSA-N 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- 101150005926 Pc gene Proteins 0.000 description 1
- 229920001774 Perfluoroether Polymers 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
- HFVNWDWLWUCIHC-GUPDPFMOSA-N Prednimustine Chemical compound O=C([C@@]1(O)CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)[C@@H](O)C[C@@]21C)COC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 HFVNWDWLWUCIHC-GUPDPFMOSA-N 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 102000007327 Protamines Human genes 0.000 description 1
- 108010007568 Protamines Proteins 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 208000021886 Pyruvate carboxylase deficiency Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- 190014017285 Satraplatin Chemical compound 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 231100000632 Spindle poison Toxicity 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- WFWLQNSHRPWKFK-UHFFFAOYSA-N Tegafur Chemical compound O=C1NC(=O)C(F)=CN1C1OCCC1 WFWLQNSHRPWKFK-UHFFFAOYSA-N 0.000 description 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 101710183280 Topoisomerase Proteins 0.000 description 1
- YCPOZVAOBBQLRI-WDSKDSINSA-N Treosulfan Chemical compound CS(=O)(=O)OC[C@H](O)[C@@H](O)COS(C)(=O)=O YCPOZVAOBBQLRI-WDSKDSINSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- UMILHIMHKXVDGH-UHFFFAOYSA-N Triethylene glycol diglycidyl ether Chemical compound C1OC1COCCOCCOCCOCC1CO1 UMILHIMHKXVDGH-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 230000006682 Warburg effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 230000004103 aerobic respiration Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 description 1
- 150000008052 alkyl sulfonates Chemical class 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 230000000735 allogeneic effect Effects 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229950010817 alvocidib Drugs 0.000 description 1
- BIIVYFLTOXDAOV-YVEFUNNKSA-N alvocidib Chemical compound O[C@@H]1CN(C)CC[C@@H]1C1=C(O)C=C(O)C2=C1OC(C=1C(=CC=CC=1)Cl)=CC2=O BIIVYFLTOXDAOV-YVEFUNNKSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 229960002749 aminolevulinic acid Drugs 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 229960002550 amrubicin Drugs 0.000 description 1
- VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 description 1
- 229960001694 anagrelide Drugs 0.000 description 1
- OTBXOEAOVRKTNQ-UHFFFAOYSA-N anagrelide Chemical compound N1=C2NC(=O)CN2CC2=C(Cl)C(Cl)=CC=C21 OTBXOEAOVRKTNQ-UHFFFAOYSA-N 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001399 anti-metabolic effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 229940045719 antineoplastic alkylating agent nitrosoureas Drugs 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- 229960003272 asparaginase Drugs 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 1
- 229950010993 atrasentan Drugs 0.000 description 1
- 229960003005 axitinib Drugs 0.000 description 1
- RITAVMQDGBJQJZ-FMIVXFBMSA-N axitinib Chemical compound CNC(=O)C1=CC=CC=C1SC1=CC=C(C(\C=C\C=2N=CC=CC=2)=NN2)C2=C1 RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
- KLNFSAOEKUDMFA-UHFFFAOYSA-N azanide;2-hydroxyacetic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OCC(O)=O KLNFSAOEKUDMFA-UHFFFAOYSA-N 0.000 description 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- LNHWXBUNXOXMRL-VWLOTQADSA-N belotecan Chemical compound C1=CC=C2C(CCNC(C)C)=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 LNHWXBUNXOXMRL-VWLOTQADSA-N 0.000 description 1
- 229950011276 belotecan Drugs 0.000 description 1
- YTKUWDBFDASYHO-UHFFFAOYSA-N bendamustine Chemical compound ClCCN(CCCl)C1=CC=C2N(C)C(CCCC(O)=O)=NC2=C1 YTKUWDBFDASYHO-UHFFFAOYSA-N 0.000 description 1
- 229960002707 bendamustine Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 206010006007 bone sarcoma Diseases 0.000 description 1
- 229960001467 bortezomib Drugs 0.000 description 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 1
- UBPYILGKFZZVDX-UHFFFAOYSA-N bosutinib Chemical compound C1=C(Cl)C(OC)=CC(NC=2C3=CC(OC)=C(OCCCN4CCN(C)CC4)C=C3N=CC=2C#N)=C1Cl UBPYILGKFZZVDX-UHFFFAOYSA-N 0.000 description 1
- 229960003736 bosutinib Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 229940006460 bromide ion Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000012928 buffer substance Substances 0.000 description 1
- 229950003628 buparlisib Drugs 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 1
- DNSISZSEWVHGLH-UHFFFAOYSA-N butanamide Chemical class CCCC(N)=O DNSISZSEWVHGLH-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229960004117 capecitabine Drugs 0.000 description 1
- 238000005251 capillar electrophoresis Methods 0.000 description 1
- 125000000609 carbazolyl group Chemical class C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 230000007963 carbohydrate restriction Effects 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 229960002115 carboquone Drugs 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 229960003261 carmofur Drugs 0.000 description 1
- 229960005243 carmustine Drugs 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000007766 cera flava Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229950009789 cetomacrogol 1000 Drugs 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229960004630 chlorambucil Drugs 0.000 description 1
- JCKYGMPEJWAADB-UHFFFAOYSA-N chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 150000001924 cycloalkanes Chemical class 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 210000005220 cytoplasmic tail Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 229950006418 dactolisib Drugs 0.000 description 1
- JOGKUKXHTYWRGZ-UHFFFAOYSA-N dactolisib Chemical compound O=C1N(C)C2=CN=C3C=CC(C=4C=C5C=CC=CC5=NC=4)=CC3=C2N1C1=CC=C(C(C)(C)C#N)C=C1 JOGKUKXHTYWRGZ-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 230000009615 deamination Effects 0.000 description 1
- 238000006481 deamination reaction Methods 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 229960005052 demecolcine Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229910052805 deuterium Inorganic materials 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229960001776 edrecolomab Drugs 0.000 description 1
- 229960000925 efaproxiral Drugs 0.000 description 1
- BNFRJXLZYUTIII-UHFFFAOYSA-N efaproxiral Chemical compound CC1=CC(C)=CC(NC(=O)CC=2C=CC(OC(C)(C)C(O)=O)=CC=2)=C1 BNFRJXLZYUTIII-UHFFFAOYSA-N 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000008387 emulsifying waxe Substances 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940095399 enema Drugs 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229950011487 enocitabine Drugs 0.000 description 1
- 230000009483 enzymatic pathway Effects 0.000 description 1
- 229960001904 epirubicin Drugs 0.000 description 1
- HCZKYJDFEPMADG-UHFFFAOYSA-N erythro-nordihydroguaiaretic acid Natural products C=1C=C(O)C(O)=CC=1CC(C)C(C)CC1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-UHFFFAOYSA-N 0.000 description 1
- 229960001842 estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229960005237 etoglucid Drugs 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 230000003492 excitotoxic effect Effects 0.000 description 1
- 231100000063 excitotoxicity Toxicity 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000004905 finger nail Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229960000961 floxuridine Drugs 0.000 description 1
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 description 1
- NBVXSUQYWXRMNV-UHFFFAOYSA-N fluoromethane Chemical compound FC NBVXSUQYWXRMNV-UHFFFAOYSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 229960004783 fotemustine Drugs 0.000 description 1
- YAKWPXVTIGTRJH-UHFFFAOYSA-N fotemustine Chemical compound CCOP(=O)(OCC)C(C)NC(=O)N(CCCl)N=O YAKWPXVTIGTRJH-UHFFFAOYSA-N 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 1
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 1
- 229950004161 ganetespib Drugs 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical compound N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 229960005277 gemcitabine Drugs 0.000 description 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000004475 heteroaralkyl group Chemical group 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- 235000009200 high fat diet Nutrition 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 229960003445 idelalisib Drugs 0.000 description 1
- YKLIKGKUANLGSB-HNNXBMFYSA-N idelalisib Chemical compound C1([C@@H](NC=2[C]3N=CN=C3N=CN=2)CC)=NC2=CC=CC(F)=C2C(=O)N1C1=CC=CC=C1 YKLIKGKUANLGSB-HNNXBMFYSA-N 0.000 description 1
- 229960001101 ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 description 1
- 229940006461 iodide ion Drugs 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 229950003599 ipsapirone Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229950001845 lestaurtinib Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- QDLAGTHXVHQKRE-UHFFFAOYSA-N lichenxanthone Natural products COC1=CC(O)=C2C(=O)C3=C(C)C=C(OC)C=C3OC2=C1 QDLAGTHXVHQKRE-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- GLXDVVHUTZTUQK-UHFFFAOYSA-M lithium;hydroxide;hydrate Chemical compound [Li+].O.[OH-] GLXDVVHUTZTUQK-UHFFFAOYSA-M 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960003538 lonidamine Drugs 0.000 description 1
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229950005239 lucanthone Drugs 0.000 description 1
- FBQPGGIHOFZRGH-UHFFFAOYSA-N lucanthone Chemical compound S1C2=CC=CC=C2C(=O)C2=C1C(C)=CC=C2NCCN(CC)CC FBQPGGIHOFZRGH-UHFFFAOYSA-N 0.000 description 1
- NDAZATDQFDPQBD-UHFFFAOYSA-N luminespib Chemical compound CCNC(=O)C1=NOC(C=2C(=CC(O)=C(C(C)C)C=2)O)=C1C(C=C1)=CC=C1CN1CCOCC1 NDAZATDQFDPQBD-UHFFFAOYSA-N 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229950008612 mannomustine Drugs 0.000 description 1
- MQXVYODZCMMZEM-ZYUZMQFOSA-N mannomustine Chemical compound ClCCNC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CNCCCl MQXVYODZCMMZEM-ZYUZMQFOSA-N 0.000 description 1
- 229960003951 masoprocol Drugs 0.000 description 1
- HCZKYJDFEPMADG-TXEJJXNPSA-N masoprocol Chemical compound C([C@H](C)[C@H](C)CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 HCZKYJDFEPMADG-TXEJJXNPSA-N 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960004961 mechlorethamine Drugs 0.000 description 1
- HAWPXGHAZFHHAD-UHFFFAOYSA-N mechlorethamine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960004635 mesna Drugs 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 1
- 229960005485 mitobronitol Drugs 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 229960003539 mitoguazone Drugs 0.000 description 1
- MXWHMTNPTTVWDM-NXOFHUPFSA-N mitoguazone Chemical compound NC(N)=N\N=C(/C)\C=N\N=C(N)N MXWHMTNPTTVWDM-NXOFHUPFSA-N 0.000 description 1
- 229960000350 mitotane Drugs 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000009126 molecular therapy Methods 0.000 description 1
- 238000002625 monoclonal antibody therapy Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229950007221 nedaplatin Drugs 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960001420 nimustine Drugs 0.000 description 1
- VFEDRRNHLBGPNN-UHFFFAOYSA-N nimustine Chemical compound CC1=NC=C(CNC(=O)N(CCCl)N=O)C(N)=N1 VFEDRRNHLBGPNN-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229950001094 ortataxel Drugs 0.000 description 1
- BWKDAMBGCPRVPI-ZQRPHVBESA-N ortataxel Chemical compound O([C@@H]1[C@]23OC(=O)O[C@H]2[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]2(C)[C@@H](O)C[C@H]4OC[C@]4([C@H]21)OC(C)=O)C3(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)CC(C)C)C(=O)C1=CC=CC=C1 BWKDAMBGCPRVPI-ZQRPHVBESA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 229960005079 pemetrexed Drugs 0.000 description 1
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-N pemetrexed Chemical compound C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-N 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 229960002340 pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 125000005010 perfluoroalkyl group Chemical group 0.000 description 1
- SZFPYBIJACMNJV-UHFFFAOYSA-N perifosine Chemical compound CCCCCCCCCCCCCCCCCCOP([O-])(=O)OC1CC[N+](C)(C)CC1 SZFPYBIJACMNJV-UHFFFAOYSA-N 0.000 description 1
- 229950010632 perifosine Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NFIYTPYOYDDLGO-UHFFFAOYSA-N phosphoric acid;sodium Chemical compound [Na].OP(O)(O)=O NFIYTPYOYDDLGO-UHFFFAOYSA-N 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229960003171 plicamycin Drugs 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229960004293 porfimer sodium Drugs 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229910001414 potassium ion Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229960004694 prednimustine Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 229950008679 protamine sulfate Drugs 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 229940117820 purinethol Drugs 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 239000012744 reinforcing agent Substances 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 description 1
- 229950009213 rubitecan Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 229960005399 satraplatin Drugs 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 1
- 229950000055 seliciclib Drugs 0.000 description 1
- 229950003647 semaxanib Drugs 0.000 description 1
- WUWDLXZGHZSWQZ-WQLSENKSSA-N semaxanib Chemical compound N1C(C)=CC(C)=C1\C=C/1C2=CC=CC=C2NC\1=O WUWDLXZGHZSWQZ-WQLSENKSSA-N 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 229960003440 semustine Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- JBJWASZNUJCEKT-UHFFFAOYSA-M sodium;hydroxide;hydrate Chemical compound O.[OH-].[Na+] JBJWASZNUJCEKT-UHFFFAOYSA-M 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000012409 standard PCR amplification Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 208000014794 superficial urinary bladder carcinoma Diseases 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 229940034785 sutent Drugs 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229950010924 talaporfin Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 210000001138 tear Anatomy 0.000 description 1
- 229960002197 temoporfin Drugs 0.000 description 1
- 229960004964 temozolomide Drugs 0.000 description 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
- 229960001278 teniposide Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- MODVSQKJJIBWPZ-VLLPJHQWSA-N tesetaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3CC[C@@]2(C)[C@H]2[C@@H](C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C(=CC=CN=4)F)C[C@]1(O)C3(C)C)O[C@H](O2)CN(C)C)C(=O)C1=CC=CC=C1 MODVSQKJJIBWPZ-VLLPJHQWSA-N 0.000 description 1
- 229950009016 tesetaxel Drugs 0.000 description 1
- 229960005353 testolactone Drugs 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Substances ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 1
- 150000003583 thiosemicarbazides Chemical class 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 229960003723 tiazofurine Drugs 0.000 description 1
- FVRDYQYEVDDKCR-DBRKOABJSA-N tiazofurine Chemical compound NC(=O)C1=CSC([C@H]2[C@@H]([C@H](O)[C@@H](CO)O2)O)=N1 FVRDYQYEVDDKCR-DBRKOABJSA-N 0.000 description 1
- 229960003087 tioguanine Drugs 0.000 description 1
- MNRILEROXIRVNJ-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=NC=N[C]21 MNRILEROXIRVNJ-UHFFFAOYSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
- 229960000303 topotecan Drugs 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960003181 treosulfan Drugs 0.000 description 1
- IUCJMVBFZDHPDX-UHFFFAOYSA-N tretamine Chemical compound C1CN1C1=NC(N2CC2)=NC(N2CC2)=N1 IUCJMVBFZDHPDX-UHFFFAOYSA-N 0.000 description 1
- 229950001353 tretamine Drugs 0.000 description 1
- 229960001727 tretinoin Drugs 0.000 description 1
- 150000004654 triazenes Chemical class 0.000 description 1
- PXSOHRWMIRDKMP-UHFFFAOYSA-N triaziquone Chemical compound O=C1C(N2CC2)=C(N2CC2)C(=O)C=C1N1CC1 PXSOHRWMIRDKMP-UHFFFAOYSA-N 0.000 description 1
- 229960004560 triaziquone Drugs 0.000 description 1
- 125000001889 triflyl group Chemical group FC(F)(F)S(*)(=O)=O 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000875 trofosfamide Drugs 0.000 description 1
- UMKFEPPTGMDVMI-UHFFFAOYSA-N trofosfamide Chemical compound ClCCN(CCCl)P1(=O)OCCCN1CCCl UMKFEPPTGMDVMI-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 229960001055 uracil mustard Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 239000010913 used oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229960003895 verteporfin Drugs 0.000 description 1
- ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N verteporfin Chemical compound C=1C([C@@]2([C@H](C(=O)OC)C(=CC=C22)C(=O)OC)C)=NC2=CC(C(=C2C=C)C)=NC2=CC(C(=C2CCC(O)=O)C)=NC2=CC2=NC=1C(C)=C2CCC(=O)OC ZQFGRJWRSLZCSQ-ZSFNYQMMSA-N 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- HHJUWIANJFBDHT-KOTLKJBCSA-N vindesine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(N)=O)N4C)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 HHJUWIANJFBDHT-KOTLKJBCSA-N 0.000 description 1
- 229960004355 vindesine Drugs 0.000 description 1
- NMDYYWFGPIMTKO-HBVLKOHWSA-N vinflunine Chemical compound C([C@@](C1=C(C2=CC=CC=C2N1)C1)(C2=C(OC)C=C3N(C)[C@@H]4[C@@]5(C3=C2)CCN2CC=C[C@]([C@@H]52)([C@H]([C@]4(O)C(=O)OC)OC(C)=O)CC)C(=O)OC)[C@H]2C[C@@H](C(C)(F)F)CN1C2 NMDYYWFGPIMTKO-HBVLKOHWSA-N 0.000 description 1
- 229960000922 vinflunine Drugs 0.000 description 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
- 229960002066 vinorelbine Drugs 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 description 1
- 229960000237 vorinostat Drugs 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
- 229950008250 zalutumumab Drugs 0.000 description 1
- 150000003751 zinc Chemical class 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Abstract
The compound that this document describes suppression transglutaminase and the compositions comprising described compound.The method that there is also described herein the compound using suppression transglutaminase in treatment of cancer.
Description
Claim of priority
This application claims the preferential of international application sequence No.PCT/CN2014/073812 submitted on March 21st, 2014
Power, it is incorporated by herein by quoting.
Background of invention
Cancerous cell depends on glycolysis and produces for the biosynthetic cellular energy of lipid and nucleotide and biology
Chemical intermediate, and the majority of " normal " cell in adult tissue utilizes aerobic respiration.Between cancerous cell and normal cell
This basic difference in terms of cellular metabolism is referred to as a watt berg's effect (Warburg Effect).Knot as this difference
Really, the pyruvate produced via glycolytic pathway is converted to lactic acid rather than for producing acetyl-CoA, and finally produces
The citrate utilized in normal tricarboxylic acid cycle.In order to compensate these energy variation and maintain tricarboxylic acid cycle, cancer is thin
Born of the same parents depend on glutamine metabolism, and this metabolism realizes by raising glutaminase active.Utilization to this phenomenon
Can realize by suppressing the glutaminase active of this rising.
Summary of the invention
This document describes the compound containing heterocycle, and pharmaceutically acceptable salt, solvate and hydrate.These are changed
Compound can be used for such as treating disease described herein by the transglutaminase in suppression patient.Additionally provide and be included in
The compositions (such as, pharmaceutical composition) of this compound provided together and these compositionss treatment such as with glutamine
Enzyme abnormal function or glutaminase active raise the purposes in the method for relevant disease and illness (including such as cancer).
In one embodiment, it is provided that the compound of formula (I) or its pharmaceutically acceptable salt:
Wherein
X is the C being optionally substituted3-C7Cycloalkylidene;
Each W, Y and Z independently be-S-,-CH=,-CH=CH-,-CH=CR1-、-CR1=CR1-,-O-,-N=,
Or-NH-, condition be at least one of W, Y and Z for-CH=,
Each W', Y' and Z' independently be-S-,-CH=,-CH=CH-,-CH=CR2-、-CR2=CR2-、-O-、-N
=or-NH-, condition is that at least one of W', Y' and Z' is for-CH=;Condition be one of W, Y and Z be-CH=CH-,-CH=
CR1-or-CR1=CR1-, and
When W is-CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of Y and Z independently be-CH=or-N
=;
When Y is-CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of W and Z independently be-CH=or-N
=;
When Z is-CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of Y and W independently be-CH=or-N
=;
Condition be two of W', Y' and Z' for CH=CH-,-CH=CR2-or-CR2=CR2-, and
When W' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, the most each Y' and Z' independently be-CH=or-N
=;
When Y' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, then each of W' and Z' independently be-CH=
Or-N=;
When Z' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, then each of Y' and W' independently be-CH=
Or-N=;
Each R1And R2Independently be-NH2、-N(R3)-C(O)-R4、-C(O)-N(R3)-R4、-N(R3)-C(O)-O-R4、-N
(R3)-C(O)-N(R3)-R4Or-N (R3)-C(O)-SR4;
Each R3Independently be hydrogen, C1-6Alkyl or aryl;
Each R4Independently be C1-6Alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloalkyl, cycloalkyl-alkyl,
Heterocyclylalkyl or heterocyclic radical, each of which R occurred by 0 to 3 time5Replace;
Each R5Independently be C1-6Alkyl, C1-6Alkoxyl ,-O-C1-6Alkylidene C1-6Alkoxyl ,-O-heterocyclic radical, C1-6Sulfur
For alkoxyl, C1-6Haloalkyl, C3-7Cycloalkyl, C3-7Cycloalkyl-alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, heterocycle
Alkyl, heterocyclic radical, cyano group, halogen, oxo ,-OH ,-OCF3、-OCHF2、-SO2-C1-6Alkyl ,-NO2、-N(R7)-C(O)-C1-6Alkane
Base ,-C (O) N (R7)2、-N(R7)S(O)1-2-C1-6Alkyl ,-S (O)2N(R7)2、-N(R7)2、-C1-6Alkylidene-N (R7)2, wherein
Described alkyl, C1-6Alkoxyl ,-O-C1-6Alkylidene C1-6Alkoxyl ,-O-heterocyclic radical, C1-6Thio alkoxy, C1-6Haloalkyl,
C3-7Cycloalkyl, C3-7Cycloalkyl-alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloheteroalkylalkyl, heterocyclic radical ,-SO2-
C1-6Alkyl ,-NO2、-N(R7)-C(O)-C1-6Alkyl ,-C (O) N (R7)2、-N(R7)S(O)1-2-C1-6Alkyl ,-S (O)2N(R7)2、-
N(R7)2, or-C1-6Alkylidene-N (R7)2The R optionally occurred by 0 to 3 time8Replace;Or two R closed on5Part, with it
The atom that connects collectively form cycloalkyl or heterocyclic radical;
Each R6Independently be hydrogen, fluorine, C1-6Alkyl ,-OH ,-NH2、-NH(CH3)、-N(CH3)2, or C1-6Alkoxyl;
Each R7Independently be hydrogen or C1-6Alkyl;
Each R8Independently be halogen, C1-6Alkyl, C1-6Haloalkyl ,-OH ,-N (R7)2, or C1-6Alkoxyl ,-O-C1-6
Alkylidene C1-6Alkoxyl, CN, NO2、-N(R7)-C(O)-C1-6Alkyl ,-C (O) N (R7)2、-N(R7)S(O)1-2C1-6Alkyl or-S
(O)2N(R7)2;
M is 0,1 or 2;
N is 0,1 or 2;
O is 1,2 or 3;And
P is 1,2 or 3.
In another embodiment, it is provided that comprise the compound of formula (I) or the compositions of its pharmaceutically acceptable salt.
In some embodiments, said composition is pharmaceutical composition.
In another embodiment, there is provided herein treatment or prevent as described herein (such as, treatment) disease,
Illness or the method for disease, including using compound described herein, its pharmaceutically acceptable salt or comprising described herein
Compound or the pharmaceutical composition of its pharmaceutically acceptable salt.
In another embodiment, there is provided herein the method such as suppressing transglutaminase in patient in need.
In some embodiments, there is provided herein the product water of reduction transglutaminase in experimenter (patient the most in need)
Flat.The method includes using the compound described herein of effective dose to experimenter in need or it is pharmaceutically acceptable
Salt, thus suppresses the level of this experimenter's GLN enzyme.
In another embodiment, there is provided herein treatment suffer from or be susceptible to suffer from and experimenter's GLN in need
Disease that the activity of the abnormal function of enzyme or the rising of transglutaminase is relevant or the method for the experimenter of disease.The method includes
Use the compound described herein step to this experimenter in need of effective dose, thus treat, prevent or alleviate this and be subject to
The disease of examination person or disease.In certain embodiments, said composition provides in pharmaceutical composition.In some embodiment
In, the method includes identifying or select to will benefit from suppressing transglutaminase or reducing the experimenter of glutamine enzyme level.Example
As, this experimenter can the level of cell or tissue sample GLN enzymatic activity based on this experimenter identify, it is used for controlling
Treat the cancer relevant to abnormal transglutaminase function or activity.In another embodiment, selected experimenter for suffering from or
Person is susceptible to suffer from disease or disease (disease being such as characterized, the such as cancer identified herein with the growth of undesirable cell or propagation
Or other neoplastic condition) patient.
In another embodiment, there is provided herein the method for cancer in treatment experimenter, the method includes: optionally,
Obtain Samples subjects;Obtain the assessment of this Samples subjects or assess this Samples subjects, wherein this Samples subjects
It is characterised by that i) low-level CAM 120/80 is expressed compared with reference standard, ii) high-caliber waveform compared with reference standard
Protein expression, or iii) low-level or drop low-level carboxylase expression of enzymes;And use to this experimenter in need
The compound described herein of effective dose in treatment.In some embodiments, this Samples subjects is characterised by i) and reference
Standard is compared low-level CAM 120/80 and is expressed and ii) high-caliber Vimentin compared with reference standard.At some
In embodiment, this Samples subjects is characterised by or is additionally characterized by compared with reference standard low-level or drops low-level
Carboxylase expression of enzymes.
In another embodiment, there is provided herein the method for cancer in treatment experimenter, this Subject characteristics is i)
Low-level CAM 120/80 is expressed compared with reference standard, ii) high-caliber Vimentin compared with reference standard, or
Iii) low-level or drop low-level carboxylase expression of enzymes;Including effective dose on experimenter's administering therapeutic in need
Compound described herein.In some embodiments, this Subject characteristics is i) low-level E-compared with reference standard
Cadherin is expressed and ii) high-caliber Vimentin compared with reference standard.In some embodiments, this experimenter
It is characterised by or is additionally characterized by compared with reference standard low-level or drop low-level carboxylase expression of enzymes.
Detailed description of the invention
In following description statement or accompanying drawing shown in the structure of component and the details of arrangement be not intended to restricted
's.Embodiment can be implemented and carried out in various manners.Wording used herein and term also be in order at description purpose and not
It is considered as restrictive." include " herein, " comprising " or " having ", " containing ", " relating to " and the use of version thereof
It is intended to project listed after which and equivalent thereof and additional project.
Compound
This document describes compound and the compositions of suppression transglutaminase.The compound of suppression transglutaminase can be used
In the disease treating such as neoplastic condition (such as cancer).
In one embodiment, it is provided that the compound of formula (I) or its pharmaceutically acceptable salt, or contained
(I) compound or the pharmaceutical composition of its pharmaceutically acceptable salt:
Wherein
X is the C being optionally substituted3-C7Cycloalkylidene;
Each W, Y and Z independently be-S-,-CH=,-CH=CH-,-CH=CR1-、-CR1=CR1-,-O-,-N=or-
NH-, condition be at least one of W, Y and Z for-CH=,
Each W', Y' and Z' independently be-S-,-CH=,-CH=CH-,-CH=CR2-、-CR2=CR2-、-O-、-N
=or-NH-, condition is that at least one of W', Y' and Z' is for-CH=;Condition be one of W, Y and Z be-CH=CH-,-CH=
CR1-or-CR1=CR1-, and
When W is CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of Y and Z independently be-CH=or-N
=;
When Y is CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of W and Z independently be-CH=or-N
=;
When Z is-CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of Y and W independently be-CH=or-N
=;
Condition be two of W', Y' and Z' for CH=CH-,-CH=CR2-or-CR2=CR2-, and
When W' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, the most each Y' and Z' independently be-CH=or-N
=;
When Y' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, then each of W' and Z' independently be-CH=
Or-N=;
When Z' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, then each of Y' and W' independently be-CH=
Or-N=;
Each R1And R2Independently be-NH2、-N(R3)-C(O)-R4、-C(O)-N(R3)-R4、-N(R3)-C(O)-O-R4、-N
(R3)-C(O)-N(R3)-R4Or-N (R3)-C(O)-SR4;
Each R3Independently be hydrogen, C1-6Alkyl or aryl;
Each R4Independently be C1-6Alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloalkyl, cycloalkyl-alkyl,
Heterocyclylalkyl or heterocyclic radical, each of which R occurred by 0 to 3 time5Replace;
Each R5Independently be C1-6Alkyl, C1-6Alkoxyl ,-O-C1-6Alkylidene C1-6Alkoxyl ,-O-heterocyclic radical, C1-6Sulfur
For alkoxyl, C1-6Haloalkyl, C3-7Cycloalkyl, C3-7Cycloalkyl-alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, heterocycle
Alkyl, heterocyclic radical, cyano group, halogen, oxo ,-OH ,-OCF3、-OCHF2、-SO2-C1-6Alkyl ,-NO2、-N(R7)-C(O)-C1-6Alkane
Base ,-C (O) N (R7)2、-N(R7)S(O)1-2-C1-6Alkyl ,-S (O)2N(R7)2、-N(R7)2、-C1-6Alkylidene-N (R7)2, wherein
Described alkyl, C1-6Alkoxyl ,-O-C1-6Alkylidene C1-6Alkoxyl ,-O-heterocyclic radical, C1-6Thio alkoxy, C1-6Haloalkyl,
C3-7Cycloalkyl, C3-7Cycloalkyl-alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloheteroalkylalkyl, heterocyclic radical ,-SO2-
C1-6Alkyl ,-NO2、-N(R7)-C(O)-C1-6Alkyl ,-C (O) N (R7)2、-N(R7)S(O)1-2-C1-6Alkyl ,-S (O)2N(R7)2、-
N(R7)2, or-C1-6Alkylidene-N (R7)2The R optionally occurred by 0 to 3 time8Replace;Or two R closed on5Part, with it
The atom that connects collectively form cycloalkyl or heterocyclic radical;
Each R6Independently be hydrogen, fluorine, C1-6Alkyl ,-OH ,-NH2、-NH(CH3)、-N(CH3)2, or C1-6Alkoxyl;
Each R7Independently be hydrogen or C1-6Alkyl;
Each R8Independently be halogen, C1-6Alkyl, C1-6Haloalkyl ,-OH ,-N (R7)2, or C1-6Alkoxyl ,-O-C1-6
Alkylidene C1-6Alkoxyl, CN, NO2、-N(R7)-C(O)-C1-6Alkyl ,-C (O) N (R7)2、-N(R7)S(O)1-2C1-6Alkyl or-S
(O)2N(R7)2;
M is 0,1 or 2;
N is 0,1 or 2;
O is 1,2 or 3;And
P is 1,2 or 3.
In one embodiment, it is provided that the compound of formula (I) or its pharmaceutically acceptable salt, or contained
(I) compound or the pharmaceutical composition of its pharmaceutically acceptable salt:
Wherein
X is the C being optionally substituted3-C7Cycloalkylidene;
Each W, Y and Z independently be-S-,-CH=,-CH=CH-,-CH=CR1-、-CR1=CR1-,-O-,-N=,
Or-NH-, condition be at least one of W, Y and Z for-CH=,
Each W', Y' and Z' independently be-S-,-CH=,-CH=CH-,-CH=CR2-、-CR2=CR2-、-O-、-N
=or-NH-, condition is that at least one of W', Y' and Z' is for-CH=;Condition be one of W, Y and Z be-CH=CH-,-CH=
CR1-or-CR1=CR1-, and
When W is CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of Y and Z independently be-CH=or-N
=;
When Y is-CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of W and Z independently be-CH=or-N
=;
When Z is-CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of Y and W independently be-CH=or-N
=;
Condition be two of W', Y' and Z' for CH=CH-,-CH=CR2-or-CR2=CR2-, and
When W' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, the most each Y' and Z' independently be-CH=or-N
=;
When Y' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, then each of W' and Z' independently be-CH=
Or-N=;
When Z' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, then each of Y' and W' independently be-CH=
Or-N=;Each R1And R2Independently be-NH2、-N(R3)-C(O)-R4、-C(O)-N(R3)-R4、-N(R3)-C(O)-O-R4、-N
(R3)-C(O)-N(R3)-R4Or-N (R3)-C(O)-SR4;
Each R3Independently be hydrogen, C1-6Alkyl or aryl;
Each R4Independently be C1-6Alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloalkyl, cycloalkyl-alkyl,
Heterocyclylalkyl or heterocyclic radical, each of which R occurred by 0 to 3 time5Replace;
Each R5Independently be C1-6Alkyl, C1-6Alkoxyl, C1-6Thio alkoxy, C1-6Haloalkyl, C3-7Cycloalkyl,
C3-7Cycloalkyl-alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloheteroalkylalkyl, heterocyclic radical, cyano group, halogen, oxo ,-
OH、-OCF3、-OCHF2、-SO2-C1-6Alkyl ,-NO2、-N(R7)-C(O)-C1-6Alkyl ,-N (R7)2, or two R closed on5Portion
Point, atom in connection collectively forms heterocyclic radical;
Each R6Independently be hydrogen, fluorine, C1-6Alkyl ,-OH ,-NH2、-NH(CH3)、-N(CH3)2, or C1-6Alkoxyl;
Each R7Independently be hydrogen or C1-6Alkyl;
M is 0,1 or 2;
N is 0,1 or 2;
O is 1,2 or 3;And
P is 1,2 or 3.
In some embodiments, X is unsubstituted cyclopropyl.In some embodiments, X is unsubstituted ring fourth
Base.In some embodiments, X is unsubstituted cyclopenta.In some embodiments, X is cyclohexyl.Some embodiment party
In case, X is suberyl.In some embodiments, X is replaced by 1 to 3 substituent group.In some embodiments, X is taken by 1
Replace for base.In some embodiments, X is replaced by 2 substituent groups.
In some embodiments, Y' is-N=.In some embodiments, Z' is-N=.In some embodiments,
W' is-S-.In some embodiments, W' is-CH=CH-.In some embodiments, W is-CH=CH-.Implement at some
In scheme, Y is-N=.In some embodiments, Z is-N=.In some aspects of these embodiments, W' is-S-, Y'
It is-N=for-N=and Z'.In some aspects of these embodiments, W is-CH=CH-, and Y is-N=, and Z is-N=.
In some aspects of these embodiments, W' is-CH=CH-, and Y' is-N=, and Z' is-N=.In these embodiments
Some aspects, W is-CH=CH-, and Y is-N=, and Z is-N=, and W' is-S-, Y' be-N=and Z' be-N=.Implement at these
Some aspects of scheme, W is-CH=CH-, and Y is-N=, and Z is-N=, and W' is-CH=CH-, Y' be-N=and Z' be-N=.
In some embodiments, o is 1.In some embodiments, p is 1.In some embodiments, o is 1 and p to be 1.
In some embodiments, m is 0.In some embodiments, n is 0.In some embodiments, m is 0 and n
It is 0.In some embodiments, R1And R2Identical.In some embodiments, R1And R2Different.
In some embodiments, m is 1.In some embodiments, n is 1.In some embodiments, n is 1 and m
It is 1.In some aspects of these embodiments, each R6It is all hydrogen.In some embodiments, R1And R2Identical.Real at some
Execute in scheme, R1And R2Different.
In some embodiments, R1And R2It is respectively-N (R3)-C(O)-R4, the most each R3For hydrogen and each R4For virtue
Alkyl or heteroarylalkyl, each of which R occurred by 0 to 3 time5Replace.In some aspects of these embodiments, R1And R2Phase
With.
In some embodiments, R1And R2It is respectively-N (R3)-C(O)-R4, the most each R3For hydrogen.These embodiment party
Some aspects of case, each R4For the R occurred by 0 to 3 time5Substituted aralkyl.In some aspects of these embodiments, R1
And R2Identical.
In some aspects of these embodiments, each R4For the R occurred by 0 time5Substituted aralkyl (such as benzyl).
In some aspects of these embodiments, each R4For the R occurred by 1 time5Substituted aralkyl (such as benzyl).Real at these
Execute some other sides of scheme, each R5It is all-N (CH3)2.At the other aspect of these embodiments, each R5All
For C1-6Alkoxyl (such as, methoxyl group or isopropoxy).At the other aspect of these embodiments, each R5It is all-O-
Heterocyclic radical (such as ,-O-oxetanes).At the other aspect of these embodiments, each R5Be all halogen (such as,
Fluorine or chlorine).At the other aspect of these embodiments, each R5It is all-NH2.Other side in these embodiments
Face, each R5It is all-SO2-CH3.At the other aspect of these embodiments, each R5It is all-NHC (O) CH3.At these
The other aspect of embodiment, each R5It is all-NO2.At the other aspect of these embodiments, each R5It is all
Cyano group.At the other aspect of these embodiments, each R5It is all C1-6Halogenated alkoxy (such as, trifluoromethoxy).?
The other aspect of these embodiments, each R5It is all C1-6Haloalkyl (such as, trifluoromethyl).These embodiment party
The other aspect of case, each R5It is all C1-6Alkyl (such as, methyl).In some aspects of these embodiments, each R4
It is all by the R of twice appearance5Substituted aralkyl (such as benzyl).At some other sides of these embodiments, two R5For
Halogen (such as, fluorine), another two R5For C1-6Alkoxyl (such as, methoxyl group).At the other aspect of these embodiments,
Each R5It is all halogen (such as, fluorine).At the other aspect of these embodiments, each R5It is all C1-6Alkoxyl is (such as,
Methoxyl group).At the other aspect of these embodiments, two R closed on5Part atom in connection is formed together
Heterocyclic ring, obtains the part of following structure:
In some aspects of these embodiments, each R4It is all the R occurred by 0 to 3 time5Substituted heteroarylalkyl (example
As, 2-pyridylmethyl, 2-pyridyl-ethyl group, 3-pyridylmethyl, 4-pyridylmethyl, 2-pyrazinyl-methyl, 2-thienyl
Methyl, 2-indolylinethyl, 4-indolylinethyl, 2-Pyrimidylmethyl or 2-benzothiazolylmethyl).In these embodiments one
A little aspects, each R4It is all the R occurred by 0 time5Substituted heteroarylalkyl (such as, 2-pyridylmethyl, 2-pyridyl-ethyl group, 3-
Pyridylmethyl, 4-pyridylmethyl, 2-pyrazinyl-methyl, 2-thienyl methyl, 2-indolylinethyl, 3-indolylinethyl,
4-indolylinethyl, 2-Pyrimidylmethyl or 2-benzothiazolylmethyl).At the other side of these embodiments, each R4It is all
The R occurred by 1 time5Substituted heteroarylalkyl (such as, 5-isoxazolyl, 2-pyridylmethyl or 3-indolylinethyl).At this
Some other sides of a little embodiments, each R5It is all C1-6Alkyl (such as, methyl).These embodiments other its
Its aspect, each R5It is all C1-6Alkoxyl (such as, methoxyl group).At the other aspect of these embodiments, each R5All
For cyano group.At the other aspect of these embodiments, each R5It is all-N (CH3)2.These embodiments other its
Its aspect, each R5It is all-NHC (O) CH3.At the other aspect of these embodiments, each R5Be all halogen (such as,
Bromo).
In some aspects of these embodiments, each R4For the R occurred by 0 to 3 time5Substituted C1-6Alkyl (such as first
Base, ethyl, n-pro-pyl or isopropyl).In some aspects of these embodiments, each R4It is all the R occurred by 0 time5Substituted
C1-6Alkyl (such as methyl, ethyl, n-pro-pyl or isopropyl).At the other side of these embodiments, each R4It is all by 1
The R of secondary appearance5Substituted C1-6Alkyl (such as methyl, ethyl or the tert-butyl group).At some other aspects of these embodiments,
Each R5It is all C1-6Thio alkoxy (such as, thiornethoxy group).At the other aspect of these embodiments, each R5All
For C1-6Haloalkyl (such as, trifluoromethyl).At the other aspect of these embodiments, each R5It is all-OH.
In some aspects of these embodiments, each R4It is all the R occurred by 0 to 3 time5Substituted aryl (such as benzene
Base).In some aspects of these embodiments, each R4It is all the R occurred by 0 time5Substituted aryl (such as benzyl).
In some aspects of these embodiments, each R4It is all the R occurred by 1 time5Substituted aryl (such as benzyl),
Wherein R5For heterocyclic radical (such as, azetidinyl), and R5Replaced by the halogen (such as, fluorine) of twice appearance.
In some aspects of these embodiments, each R4It is all the R occurred by 0 to 3 time5Substituted heterocyclic radical is (such as,
3-tetrahydrofuran base).In some aspects of these embodiments, each R4It is all the R occurred by 0 time5Substituted heterocyclic radical base
(such as, 3-tetrahydrofuran base).
In some aspects of these embodiments, each R4It is all the R occurred by 0 to 3 time5Substituted cycloheteroalkylalkyl (example
As, 2-oxolane ylmethyl).In some aspects of these embodiments, each R4It is all the R occurred by 0 time5Substituted miscellaneous
Cyclylalkyl (such as, 2-oxolane ylmethyl).In some aspects of these embodiments, each R4For the R occurred by 0 time5
Substituted cycloheteroalkylalkyl, and by following representation:
In some aspects of these embodiments, each R4It is all the R occurred by 0 to 3 time5Substituted cycloalkyl is (such as,
Cyclopenta).In some aspects of these embodiments, each R4It is all the R occurred by 0 time5Substituted cycloalkyl (such as, ring penta
Base).
In some aspects of these embodiments, each R4It is all the R occurred by 0 to 3 time5Substituted cycloalkyl-alkyl (example
As, Cvclopropvlmethvl).In some aspects of these embodiments, each R4It is all the R occurred by 0 time5Substituted cycloalkyl alkane
Base (such as, Cvclopropvlmethvl).
In some aspects of these embodiments, each R4It is all the R occurred by 0 to 3 time5Substituted C1-6Thiazolinyl is (such as,
Vinyl).In some aspects of these embodiments, each R4It is all the R occurred by 1 time5Substituted C1-6Thiazolinyl (such as, second
Thiazolinyl).At some other aspects of these embodiments, each R5It is all heteroaryl (such as, 2-pyridine radicals).
In some aspects of these embodiments, a R4For the R occurred by 0 time5Substituted C1-6Alkyl (such as, first
Base), other R4For the R occurred by 1 time5Substituted heteroarylalkyl (such as, 3-indolylinethyl), wherein R5For C1-6Alkyl
(such as, methyl).
In some aspects of these embodiments, a R4For the R occurred by 0 time5Substituted C1-6Alkyl (such as, first
Base), other R4For the R occurred by 1 time5Substituted heteroarylalkyl (such as, 2-pyridine radicals), wherein R5For heterocyclic radical (such as,
Azetidinyl), and R5The halogen substiuted (such as, fluorine) occurred by 2 times.
In some aspects of these embodiments, a R4For the R occurred by 0 time5Substituted C1-6Alkyl (such as, first
Base), other R4For the R occurred by 1 time5Substituted heteroarylalkyl (such as, 3-indolylinethyl), wherein R5For C1-6Alkyl
(such as, methyl).
In some aspects of these embodiments, a R4For C1-6Alkyl (such as, methyl), other R4For heteroarylalkyl
(such as, 2-pyridylmethyl), the R that each of which is occurred by 0 time5Replace.
In some aspects of these embodiments, a R4For the R occurred by 0 time5Substituted heteroarylalkyl (such as, 2-pyrrole
Piperidinyl base), other R4For the R occurred by 1 time5Substituted aralkyl (such as, benzyl), wherein R5For C1-6Alkoxyl is (such as,
Methoxyl group).
In some aspects of these embodiments, a R4For the R occurred by 0 time5Substituted C1-6Alkyl (such as, first
Base), other R4For the R occurred by 1 time5Substituted aralkyl (such as, benzyl), wherein R5For C1-6Alkoxyl (such as, methoxy
Base).
In some embodiments, R2For-NH2, and R1For-N (R3)-C(O)-R4, wherein R3For hydrogen and R4For being gone out by 0 time
Existing R5Substituted heteroarylalkyl (such as, 2-pyridylmethyl).
In some embodiments, each R6It is all H.
In some embodiments, the compounds represented of the formula (II) of formula (I):
Wherein R1、R2、R3、R4、R5、R6, o, p, m, n and X be as defined in formula (I).
In some embodiments, the compounds represented of the formula (III) of formula (I):
Wherein R1、R2、R3、R4、R5、R6, o, p, m, n and X be as defined in formula (I).
In some embodiments, the compounds represented of the formula (IIa) of formula (I) or (II):
Wherein R1、R2、R3、R4、R5、R6, o, p, m, n and X be as defined in formula (I).
In some embodiments, the compounds represented of the formula (IIIa) of formula (I) or (III):
Wherein R1、R2、R3、R4、R5、R6, o, p, m, n and X be as defined in formula (I).
In some embodiments, the compounds represented of the formula (IIb) of formula (I) or (II) or (IIa):
Wherein R1、R2、R3、R4、R5、R6, o, p, m, n and X be as defined in formula (I).
In some embodiments, the compounds represented of the formula (IIIb) of formula (I) or (III) or (IIIa):
Wherein R1、R2、R3、R4、R5、R6, o, p, m, n and X be as defined in formula (I).
In some embodiments, the compounds represented of the formula (IV) of formula (I):
Wherein R1、R2、R3、R4And R5As defined in formula (I), and q is 0,1,2,3 or 4.
In some embodiments, the compounds represented of the formula (V) of formula (I):
Wherein R1、R2、R3、R4And R5As defined in formula (I), and q is 0,1,2,3 or 4.
In some embodiments, the compounds represented of the formula (IVa) of formula (I) or (IV):
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (Va) of formula (I) or (V):
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (IVb) of formula (I) or (IV):
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (Vb) of formula (I) or (V):
Wherein R4、R5With q as defined in formula (V).In some embodiments, formula (I) or the formula of (IV)
(IVc) compounds represented:
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (Vc) of formula (I) or (V):
Wherein R4、R5With q as defined in formula (V).
In some embodiments, the compounds represented of the formula (VIa) of formula (I) or (IV):
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (VIIa) of formula (I) or (V):
Wherein R4、R5With q as defined in formula (V).In some embodiments, formula (I) or the formula of (IV)
(VIb) compounds represented:
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (VIIb) of formula (I) or (V):
Wherein R4、R5With q as defined in formula (V).
In some embodiments, the compounds represented of the formula (VIc) of formula (I) or (IV):
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (VIIc) of formula (I) or (V):
Wherein R4、R5With q as defined in formula (V).
In some embodiments, the compounds represented of the formula (VIIIa) of formula (I) or (IV):
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (IXa) of formula (I) or (V):
Wherein R4、R5With q as defined in formula (V).
In some embodiments, the compounds represented of the formula (VIIIb) of formula (I) or (IV):
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (IXb) of formula (I) or (IV):
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (VIIIc) of formula (I) or (IV):
Wherein R4、R5With q as defined in formula (IV).
In some embodiments, the compounds represented of the formula (IXc) of formula (I) or (IV):
Wherein R4、R5With q as defined in formula (IV).
In certain embodiments, the compound during the exemplary compounds of Formulas I includes table 1 and described in embodiment.Example
Algoscopy as described in by embodiment, can test the ability of its suppression transglutaminase to compound described herein.
In table 1, the exemplary compounds of display is as follows.
Table 1:
The most also include the compound of formula I or the method for the compound of any embodiment described herein, bag
Include and make
WithReaction, wherein G is
Leaving group, such as halogen ,-OH, perfluoro alkyl sulfonic acid root (such as, trifluoromethanesulfonic acid root), tosylate, methanesulfonate,
Or NH2。
In some embodiments, preceding method includes making
React to produceStep (1);And makeThe step (2) of reaction.
In some embodiments, the compound of the compound of formula I or any embodiment described herein
Method includes making
WithReaction,
Wherein G is leaving group, such as halogen ,-OH, perfluoro alkyl sulfonic acid root (such as, trifluoromethanesulfonic acid root), tosylate, first
Sulfonate radical or NH2。
In some embodiments, preceding method includes makingWithReact with
ProduceStep (1);
MakeWithReact to produce
Step (2) and makeWithThe step (3) of reaction.
Compound described herein can use multiple synthetic technology to prepare, described in example the most provided herein
Those technology.As technical staff is to understand, the method for the synthesis compound of multiple formulas herein is for ordinary skill
Personnel will be apparent from.It addition, each synthesis step can be carried out by substituting order or sequence, to obtain desired chemical combination
Thing.Can be used for synthesizing the synthesis chemical conversion of compound described herein and blocking group method (protection and deprotection) in ability
Territory is known, and such as including described in the documents below: R.Larock, Comprehensive
Organic Transformations, VCH publishing house (1989);T.W.Greene and P.G.M.Wuts, Protective
Groups in Organic Synthesis, second edition, John Wiley and Sons (1991);L.Fieser and
M.Fieser,Fieser and Fieser's Reagents for Organic Synthesis,John Wiley and
Sons(1994);And L.Paquette compiles, Encyclopedia of Reagents for Organic Synthesis,
John Wiley and Sons (1995) and later release thereof.
Compound provided herein can contain one or more asymmetric centers, and therefore with racemate and raceme
Presented in mixture, single enantiomer, independent non-corresponding isomer and non-corresponding isomer mixture.These are changed
In the range of these type of isomeric form all of compound are expressly included in.Unless otherwise directed, otherwise when compound be by knot
Structure is named or describes and do not indicate spatial chemistry, and when there is one or more chiral centre, it is thus understood that represent this change
The all possible stereoisomer of compound.Compound provided herein can also containing can limit key rotate (such as, by ring or
The existence of double bond and the restriction that causes) key (such as, carbon-carbon bond).Therefore, all of cis/trans and E/Z isomer are the brightest
Really it is included.
Compound provided herein (such as, the compound of Formulas I) can also comprise one or more isotope and replace.Citing
For, H can in any isotope form, including1H、2H (D or deuterium) and3H (T or tritium);C can be in any isotope shape
Formula, including12C、13C and14C;O can in any isotope form, including16O and18O;Etc..Compound provided herein is also
Can represent by multiple tautomeric form, in these cases, include clearly compounds described herein all mutually
Becoming isomeric form, even if single tautomeric form may be illustrate only, (such as, the alkylation of loop systems can cause multiple position
The alkylation of point;In all these product are expressly included in).All these isomeric form of these compounds are the brightest
Really it is included.In all crystal forms of compound described herein are expressly included in.
Compound provided herein includes these compounds itself, and its salt and its prodrug (if appropriate).Lift
For example, salt can be formed between the substituent group (such as, amino) of positively charged in anion and compound described herein.Suitable
Close anion include chloride ion, bromide ion, iodide ion, sulfate radical, nitrate anion, phosphate radical, citrate, methanesulfonate, three
Fluoroethanoic acid root and acetate.Similarly, can electronegative substituent group (example in cation and compound described herein
Such as, carboxylate radical) between form salt.Be suitable for cation include sodium ion, potassium ion, magnesium ion, calcium ion and ammonium sun from
Son, such as trimethyl ammonium ion.The example of prodrug includes ester and other pharmaceutically acceptable derivates, and they are being executed to experimenter
Reactive compound can be provided after with.
Compound provided herein can be modified by additional suitable functional group, biological with selected by strengthening
Matter, such as, targeting particular organization.These modifications are well known in the art, and enter given biological compartment (example including increasing
As, blood, lymphsystem, central nervous system) biological penetration, increase oral administration biaavailability, increase dissolubility with permit
Permitted used by injection, change metabolism and change discharge rate those.
In an alternative embodiment, compound described herein can serve as platform or skeleton, these platforms or skeleton
Can be used in combinatorial chemistry technique to prepare derivant and/or the chemical libraries of compound.The derivant of these compounds and
Storehouse has biological activity and can be used for differentiating and design the multiple compound with given activity.It is suitable for use with described herein
The combination technique of compound be well known in the art, such as Obrecht, D. and Villalgrodo, J.M., Solid-
Supported Combinatorial and Parallel Synthesis of Small-Molecular-Weight
Compound Libraries, Pergamon-Elsevier Science Limited (1998) are illustrated, including such as
" split and merge (split and pool) " or " parallel " synthetic technology, solid phase and solution phase techniques, and coding techniques (ginseng
See, such as, Czarnik, A.W., Curr.Opin.Chem.Bio., (1997) 1,60) etc..Therefore, an embodiment relates to
Compound described herein is used to produce derivant or the method for chemical libraries, including: 1) main body including multiple hole is provided;2) to
Each hole is provided one or more compounds identified by method described herein;3) in each hole, provide other one
Individual or multi-chemical;4) one or more obtained products are isolated from each hole.Alternate embodiment is directed to use with this
The compound that literary composition describes produces derivant or the method for chemical libraries, including: 1) provide one or more to be connected to solid support
Compound described herein;2) one or more are connected to solid support to treat this with one or more other chemicals
The compound identified by method described herein;3) isolate obtained one or more from this solid support to produce
Thing.In the method being described above, can by " label " mark or mark part be connected to compound described herein or its
Derivant and/or separate from compound described herein or derivatives thereof, to promote desired product or its intermediate
Follow the trail of, identify or separate.These parts are known in this field.Chemicals used in method mentioned above is permissible
Including such as solvent, reagent, catalyst, blocking group and Deprotection reagent etc..The example of these chemicals is this paper institute
Those occurred in the different synthesis mentioned and blocking group Chemistry Teaching Material and paper.
Definition
Term " halogen " or " halogen " refer to any group in fluorine, chlorine, bromine or iodine.
Term " alkyl " refers to that it can be straight or branched containing the saturated or aliphatic unsaturated hydrocarbon specifying carbon number.
For example, C1-C12Alkyl indicates this group can have 1 to 12 (including end points) carbon atom wherein.Term " alkane
Base " include alkenyl part.Term " haloalkyl " refer to one or more hydrogen atom by the alkyl of halogen displacement, including all hydrogen all
By the moieties (such as perfluoroalkyl) of halogen displacement.Term " aryl alkyl " or " aralkyl " refer to that alkyl hydrogen atom is fragrant
The moieties of base group displacement.Aralkyl includes the group replaced by aromatic yl group more than a hydrogen atom." aryl alkane
Base " or the example of " aralkyl " include benzyl, 2-phenylethyl, 3-phenyl propyl, 9-fluorenyl, benzhydryl and trityl
Group.
Term " alkylidene " or " ring alkylidene " refer to divalent alkyl or cycloalkyl, such as-CH2-、-CH2CH2-and-
CH2CH2CH2-。
Term " thiazolinyl " refers to straight chain or the branched hydrocarbon chains containing 2 to 12 carbon atoms and having one or more double bond.Alkene
The example of base group includes but not limited to, pi-allyl, acrylic, crotyl, 3-hexenyl and 3-octenyl.The one of double key carbon
The individual junction point that can be optionally alkenyl group.
Term " alkoxyl " refers to-O-alkyl group.Term " halogenated alkoxy " refers to that one or more hydrogen atom is put by halogen
The alkoxyl changed, including all hydrogen the most by the alkoxy portion (such as perfluoro alkoxy) of halogen displacement.
Term " aryl " refers to monocycle, dicyclo or tricyclic aromatics loop systems, and any annular atoms wherein can being replaced is all
(such as, being substituted with one or more substituents) can be replaced.The example of aryl moiety includes but not limited to, phenyl, naphthyl and
Anthryl.Except as otherwise noted, otherwise any annular atoms in aryl all can be substituted with one or more substituents.
As used herein, term " cycloalkyl " includes ring-type, dicyclo, three rings or multi-ring non-aromatic with 3 to 12 carbon
Groups.Any commutable annular atoms all can be replaced (such as, being substituted with one or more substituents).Group of naphthene base can
Containing fused rings or volution.Fused rings is the ring of total common carbon atom.The example of cycloalkyl moiety includes but not limited to, ring third
Base, cyclohexyl, methylcyclohexyl, adamantyl and norcamphanyl.
As used herein, term " cycloalkyl-alkyl " refers to the alkyl being substituted by cycloalkyl.
Term " heterocyclic radical " or " heterocyclic group " refer to 3-to 14-unit non-aromatic ring structure (such as, 3-to 14-ring, more excellent
Elect 3-to 7-ring as), its ring structure includes one to four hetero atom independently selected from O, N and S.Heterocyclic radical or heterocyclic radical
Fused rings or volution can be contained in group.Heterocycle can also be multi-ring, and each group has such as 5-7 ring members.Term " heterocyclic radical "
Or " heterocyclic group " includes saturated and fractional saturation heterocyclyl structures.Hetero atom is optionally the company of heterocyclyl substituent
Contact.
Term " heteroaryl " refer to have 1 to 3 ring hetero atom (if monocycle), 1 to 6 ring hetero atom (if
Dicyclo) or 1 to 9 ring hetero atom (if three rings) 5-14 unit (that is, 5-8 unit monocycle, 8-12 unit dicyclo or
11-14 unit three rings) aromatic rings system, described ring hetero atom independently selected from O, N and S (such as, if being monocycle, double respectively
Ring or three rings, then have 1-3,1-6 or 1-9 ring hetero atom N, O or S).Any commutable annular atoms all can be replaced
(such as, being substituted with one or more substituents).
Containing one or more hetero atoms and fragrance with non-aromatic ring (wherein from loop systems to molecule remainder
Junction point be by non-aromatic ring) dicyclo and the loop systems of three rings be considered as heterocyclic radical.Aryl or heteroaryl and ring
Alkyl or heterocyclic radical condense and from loop systems to the junction point of molecule remainder be the dicyclo by aromatic rings or three ring rings
System is considered as aryl or heteroaryl groups.
As used herein, term " cycloheteroalkylalkyl " refers to the alkyl replaced by heterocyclic group.
As used herein, term " heteroarylalkyl (hetaralkyl) " and " heteroarylalkyl (heteroaralkyl) " refer to by
The substituted alkyl of heteroaryl groups.The ring hetero atom of compound provided herein includes N-O, S (O) and S (O)2。
Except as otherwise noted, otherwise aryl, heteroaryl, cycloalkyl and heterocyclyl groups, either single or conduct
A part (such as, the aryl moiety of aralkyl) for group, is the most optionally replaced at one or more commutable atoms
Base replaces, and these substituent groups are independently selected from halogen ,-C ≡ N, C1-C4Alkyl ,=O ,-ORb、-ORb’、-SRb、-SRb’、-(C1-
C4Alkyl)-N (Rb)(Rb)、-(C1-C4Alkyl)-N (Rb)(Rb’)、-N(Rb)(Rb)、-N(Rb)(Rb’)、-O-(C1-C4Alkyl)-N
(Rb)(Rb)、-O-(C1-C4Alkyl)-N (Rb)(Rb’)、-(C1-C4Alkyl)-O-(C1-C4Alkyl)-N (Rb)(Rb)、-(C1-C4Alkane
Base)-O-(C1-C4Alkyl)-N (Rb)(Rb’)、-C(O)-N(Rb)(Rb)、-(C1-C4Alkyl)-C (O)-N (Rb)(Rb)、-(C1-C4
Alkyl)-C (O)-N (Rb)(Rb’)、-ORb’、Rb’、-C(O)(C1-C4Alkyl) ,-C (O) Rb’、-C(O)N(Rb’)(Rb)、-N(Rb)C
(O)(Rb)、-N(Rb)C(O)(Rb’)、-N(Rb)SO2(Rb)、-SO2N(Rb)(Rb)、-N(Rb)SO2(Rb’) and-SO2N(Rb)
(Rb’), any of which alkyl substituent is the most optionally by-OH ,-O-(C1-C4Alkyl), halogen ,-NH2、-NH(C1-C4Alkyl)
Or-N (C1-C4Alkyl)2In one or more be further substituted with;
Each RbIndependently selected from hydrogen and-C1-C4Alkyl;Or
Two RbForming 4-to 8-unit heterocyclic radical together with the nitrogen-atoms being connected with them, this heterocyclic radical optionally comprises one
Other hetero atom selected from N, S and O;And
Each Rb’Independently selected from C3-C7Carbocylic radical, phenyl, heteroaryl and heterocyclic radical, wherein at described phenyl, cycloalkanes
One or more on base, heteroaryl or heterocyclic substituent may replace position optionally by-(C1-C4Alkyl) ,-(C1-C4Halothane
Base) ,-OH ,-O-(C1-C4Alkyl) ,-O-(C1-C4Fluoroalkyl), halogen ,-NH2、-NH(C1-C4Alkyl) or-N (C1-C4Alkyl)2
In one or more be further substituted with.
Heterocyclyl groups, the either single or part as group, the most optionally one or more any
By epoxide (=O) ,-C on commutable nitrogen-atoms1-C4Alkyl or the substituted C of fluorine1-C4Alkyl is replaced.
Term " is replaced " and refers to that hydrogen atom is by another group displacement.
Term " optionally " pointer to the inhibitory action of transglutaminase than other target exceed at least 2 times, 3 times, 4
Again, 5 times, 6 times or 10 times.
As used herein, term " inhibitor " instigates the enzymatic activity of transglutaminase measurably to slow down, stop, reducing
Or the reagent of the level that inactivation is to decrease below transglutaminase normal activity level.Glutamine enzyme inhibitor can be peptide
Or nucleic acid (such as glutamic acid).Can be by measuring the transglutaminase activity when accepting this agent treated directly or indirectly
Assess to determine if it is inhibitor.The activity of this reagent can be measured by such as relative comparison material.In some cases,
The measured activity of reagent is the inhibitory action for transglutaminase.
As used herein, term " is obtained " and refers to be obtained by " directly obtaining " or " indirectly obtaining " physical entity or value
Must be to the proprietary rights of this physical entity maybe this value (such as digital value)." directly obtain " process of implementing that refers to (such as, to implement to close
Become or the method for analysis) obtain this physical entity or value." indirectly obtain " and refer to (the most directly obtain from the opposing party or source
Third party's laboratory of this physical entity or value) receive this physical entity or value.Directly obtain physical entity to include implementing one
Process, this process includes the physical change of physical material (such as, raw material).Exemplary variations includes by two or more raw materials
Prepare physical entity;Shear or fragmentation material;Isolated or purified material;By mixed for the synthesis of two or more separate group of entities
Compound;Carrying out chemical reaction, this chemical reaction includes fracture or forms covalently or non-covalently key.Directly acquired value includes implementing
One process including sample or the additionally physical change of material, such as, implement to include material (such as sample, analyte or reagent)
The analysis process (sometimes herein called " physical analysis ") of middle physical change, implements analysis method, such as, includes following one
Kind or multiple method: from another kind of material isolated or purified one material, such as analyte or fragment or it other derive
Thing;By analyte or its fragment or other derivant and another kind of material (such as buffer, solvent or reactant) combination;
Or change analyte or its fragment or the structure of other derivant, such as by first and second atom in this analyte
Between rupture or form covalently or non-covalently key;Or by changing reagent or its fragment or the structure of other derivant, such as
By rupturing between first and second atom of this reagent or forming covalently or non-covalently key.
When " acquisition sample " term is as used herein, refer to that sample is (such as, by " directly obtaining " or " indirectly obtaining "
Tissue sample or nucleic acid samples) obtain the proprietary rights of this sample." directly obtain sample " and be meant to implement a process (example
As, implement physical method, such as operation or extraction) obtain this sample." indirectly obtain sample " and refer to from the opposing party or source (example
As directly obtained third party's laboratory of this sample) receive this sample.Directly obtain sample to include implementing a process, this mistake
Journey includes the physical change in physical material, this physical material for example, raw material, such as tissue, such as tissue in people patient or it
The front tissue separated from patient.Exemplary variations includes being prepared physical entity by raw material, dissects or scrapes undertissue;Isolated or purified
Material (such as sample tissue or nucleic acid samples);By two or more separate combination of entities resulting mixtures;Carry out including breaking
Split or formed the chemical reaction of covalently or non-covalently key.Directly obtaining sample to include implementing a process, this process includes sample
Or the physical change in another material, such as, as described above.
As used herein, the CAM 120/80 expression of " relatively low " refers to thin at epithelium with CAM 120/80 compared with reference standard
Expression in born of the same parents compares relatively low, reduction or non-existent CAM 120/80 expression, as by side as known in the art
Any one in method, such as documents below is characterized: (Yauch etc., (2005) Clin Cancer Res 11:24;
Savagner etc., (2010) Ann Oncol.21 (suppl7): vii89;Thiery etc., (2002) Nature Reviews
Cancer 2 (6): 442).
As used herein, the Vimentin level of " higher " refers to Vimentin in epithelial cell compared with reference standard
Expression compare Vimentin level that is higher or that increase, as by method as known in the art, such as with hereafter
Any one in offering is characterized: (Yauch etc., (2005) Clin Cancer Res 11:24;Savagner etc., (2010)
Ann Oncol.21 (suppl7): vii89;Thiery etc., (2002) Nature Reviews Cancer 2 (6): 442).
As used herein, relatively low compared with reference standard " or the pyruvate carboxylase expression of " reduction " refer to as by
The expression in epithelial cell of any one CAM 120/80 characterized in method as known in the art, such as documents below
Level compares relatively low, reduction or non-existent CAM 120/80 expression: (Yauch etc., (2005) Clin Cancer Res
11:24;Savagner etc., (2010) Ann Oncol.21 (suppl7): vii89;Thiery etc., (2002) Nature
Reviews Cancer 2 (6): 442).
As used herein, " cancer " and " tumor " are the terms of synonym.Term " cancer " or " tumor " refer to have carcinogenic carefully
The existence of the typical characteristic cell of born of the same parents, as uncontrolled propagation, immortality, metastatic potential, quickly growth and multiplication rate with
And some characteristic morphologic feature.Cancerous cell often form in tumor, but these cells can separately exist in animal body,
Can be maybe non-tumorigenic cancer cells, such as leukaemia.These cells can have the typical characteristic of mesenchymal cell, as following
Any one in document is characterized: (Yauch etc., (2005) Clin Cancer Res 11:24;Savagner etc., (2010)
Ann Oncol.21 (supplementary issue 7): vii89;Thiery etc., (2002) Nature Reviews Cancer 2 (6): 442).
Abbreviation Me, Et, Ph, Tf, Nf, Ts, Ms represent methyl, ethyl, phenyl, trifluoromethane sulfonyl group, nine fluorine fourths respectively
Alkane sulfonyl, p-toluenesulfonyl and methane sulfonyl.This area has the abbreviation that the organic chemist of common skill is utilized
More fully inventory see Journal of Organic Chemistry (Journal of Organic Chemistry) each volume the first phase in;
This inventory typically appear in entitled standardized abbreviations inventory (Standard List of Abbreviations) table in.Institute
All abbreviations that stating has the organic chemist of common skill to be utilized in abbreviation contained in inventory and this area are all passed through to draw
With being expressly incorporated herein.
The method of assessment compound
Glutaminase active can be monitored by the generation of detection product glutamic acid or ammonia.In some embodiments
In, measure the generation of glutamic acid, because ammonia is any one product of multiple biological respinse.
Glutamic acid produce can be measured by any one in multiple standards method as known in the art, such as chemistry and
Chromatographic detection method, and utilize the conjugate enzyme of NADH and glutamte dehydrogenase to measure.Extracellular glutamate concentration can also be
Internal use microdialysis as known in the art method is measured.It is based on micro-for measuring a kind of applicable method of glutamic acid
Two step measurements of amount titration, in this mensuration, glutamte dehydrogenase makes the glutamic acid deamination quantitatively formed in initial step
Base, obtains the NADH (Godfrey) etc. of equivalent, and 1977;Kvamme etc., 1985), can detect with spectrophotography subsequently.
Therapeutic Method
In one embodiment, it is provided that for treating or preventing the disease of (such as treatment), disease as described herein
Suffer from or the method for disease, including administered compound, the pharmaceutically acceptable salt of compound or comprise compound described herein
The pharmaceutical composition of (such as, the compound in formula (I) or table 1).
Compound described herein and compositions can be used to the cell the most in vitro or in isolated culture, or such as exist
Internal be applied to experimenter, with treatment, prevent and/or diagnose various disease conditions, including the most described below those.
As used herein, term " treatment (treat/treatment) " is defined as applying or using individually or with second
The united compound of compound to experimenter, such as patient;Or apply or use this compound to from suffering from disease (such as,
As described herein disease), the symptom with disease or the tissue having the experimenter (such as patient) of tendency of ill disease to separate
Or cell, such as cell line, with reach to cure, cure, alleviate, alleviate, change, correct, improve, improve or affect this disease,
One or more symptoms of this disease or the tendency suffering from this disease (such as, prevent at least one symptom of this disease or delay this
The outbreak of at least one symptom of disease) purpose.
As used herein, the amount of effective sanatory compound, or " therapeutically effective amount " refer to single or multiple agent
Amount at treatment cell, or is cured, alleviates, alleviates or is improved and suffer from the experimenter of disease and exceed and do not exist after experimenter uses
The amount of the compound of situation desired in the case of this treatment.
As used herein, effectively prevent the amount of the compound of disease, or " effective dose in prevention " of compound refers to list
Secondary or multidose effectively prevents or delays outbreak or the appearance of recurrence of the symptom of disease or this disease after experimenter uses
Amount.
It is the as used herein of synonym with " experimenter " as used herein the term " patient ", refers to become or have become as
Treatment, the animal of object observed and/or test, typically the mankind (that is, the sex of any age cohort, such as
Section patient or adult patients), or other mammal, such as primate (such as machin, Rhesus Macacus);Commercial relevant
Mammal, such as cattle, pig, horse, sheep, goat, cat and/or Canis familiaris L.;And/or birds, including commercial relevant birds, as chicken,
Duck, goose and/or turkey.When this term and compound or medicine use be used in combination time, then this patient has become as treatment, sees
Examine and/or this compound or the object of medicament administration.
Cancer
Method described herein may be used for any cancer, such as national cancer institute (National Cancer
Institute) those described by.Can be estimated cancer determining whether it uses method described herein.Exemplary
Cancer may include but be not limited to pulmonary carcinoma, such as nonsmall-cell lung cancer;Breast carcinoma, such as three negative breast cancer;Or hepatocarcinoma, bone
Sarcoma, lipoma, chondrosarcoma or mesothelioma.In some embodiments, this cancer is selected from colon cancer, renal cell carcinoma, acute
Myelomatosis (AML), melanoma and multiple myeloma.
This cancer can be primary tumor, is i.e. positioned at the anatomical site that tumor growth is initial.This cancer can also be
Transfer, i.e. occur at least the second anatomical site being different from the initial anatomical site of tumor growth.This cancer can be
Relapse cancer, i.e. the cancer after the treatment and reappeared after this cancer detection is less than a period of time.Relapse cancer can solve
Cut open and on, be positioned primary tumor partly, the most anatomically near primary tumor;Regionally it is positioned primary tumor,
Such as it is positioned in the lymph node near primary tumor;Or it is located remotely from primary tumor, it is located remotely from former the most anatomically
In the region of beginning tumor.
Cancer combination treatment
In some embodiments, compound described herein is to execute together with the treatment of cancer other with one or more
With.Exemplary cancers treatment includes, such as: chemotherapy, targeted therapies (such as antibody therapy), immunotherapy and hormonotherapy.
Under these each examples for the treatment of are provided in.
Chemotherapy
In some embodiments, compound described herein is to use together with one or more chemotherapy.Chemistry
Therapy is with destroying the treatment of cancer that the medicine of cancerous cell is carried out." chemotherapy " impact the most generally quickly division
The cytotoxic drug of cell, is contrasted with targeted therapies.Chemotherapy drugs divides with various possible mode interference cells
Split, the separation of the chromosome replicating or being newly formed of such as interference DNA.Chemotherapeutic most of form all targeting are all quickly
The cell of division, is not specific to cancerous cell, but specificity to a certain degree may be from can not repairing in many cancerous cell
DNA damage, and normal cell is the most permissible.
The example of chemotherapeutant used in cancer therapy includes such as antimetabolic species (such as, folic acid, purine and phonetic
Piperidine derivatives) and alkylating agent class (such as, nitrogen mustards, nitrosoureas, platinum, alkyl sulfonates, hydrazine, Triazenes, nitrogen
Third pyridine class, spindle poison, cytotoxic agent class, topoisomerase enzyme inhibitor class and other).Exemplary Agents includes A Rou ratio
Star, D actinomycin D, alitretinoin (Alitretinon), hexamethyl melamine, aminopterin, aminolevulinic acid, amrubicin, peace
Acridine, anagrelide, arsenic trioxide, asparaginase, atrasentan, Belotecan, Bexarotene, bendamustine, rich
Bleomycin, bortezomib, busulfan, camptothecine, capecitabine, carboplatin, carboquone, carmofur, carmustine, celecoxib,
Chlorambucil, chlormethine, cisplatin, cladribine, clofarabine, Ke Lita enzyme, cyclophosphamide, cytosine arabinoside, dacarbazine, more
Mildew element, daunomycin, decitabine, Demecolcine, Docetaxel, doxorubicin, Efaproxiral, department of Erie not, according to sand
Lu Xing, enocitabine, epirubicin, estramustine, etoglucid, etoposide, floxuridine, fludarabine, fluorouracil
(5FU), fotemustine, gemcitabine, Ge Li get implant, hydroxyurea (Hydroxycarbamide), hydroxyurea
(Hydroxyurea), idarubicin, ifosfamide, irinotecan, Yi Luofufen, ipsapirone, La Luotasai, folinic acid,
Mycocet, daunomycin liposome, lonidamine, lomustine, lucanthone, mannomustine, masoprocol, American and French
Logical sequence, purinethol, mesna, methotrexate, MAL, mitobronitol, mitoguazone, mitotane, mitogen are mould
Element, mitoxantrone, nedaplatin, nimustine, Ao Limosen, Ao Maxitaxin, Ortataxel, oxaliplatin, Pacific Ocean purple
China fir alcohol, pegaspargase, pemetrexed, pentostatin, Pirarubicin, a China fir fine jade, plicamycin, porfimer sodium, prednimustine,
Procarbazine, thunder are for Qu Sai, Reynolds Mo Siting, Rubitecan, 1-(2-C-cyano-2-dioxy-BETA-D-arabino-pentofuranosyl)-N4-palmitoyl cytosine, semustine, Sai Xima collection, Satraplatin JM216 BMS 182751, chain assistant
Star, talaporfin, Tegafur-uracil mixt., temoporfin, temozolomide, teniposide, tesetaxel, testolactone, tetranitrate,
Phosphinothioylidynetrisaziridine, tiazofurine, thioguanine, for pyrrole method, topotecan, ET-743, triaziquone, triethylene melamine, three
Close platinum (Triplatin), retinoic acid, treosulfan, trofosfamide, uracil mustard, cut down soft than star, Verteporfin, vincaleucoblastine,
Vincristine, vindesine, vinflunine, vinorelbine, Vorinostat, left soft than star and other Carbazole alkaloid described herein
Agent or cytotoxic agent.
Owing to some medicines are used together more preferable than being used alone, therefore the most simultaneously with two or more drug administrations.
Generally, use two or more chemotherapeutic agents as combinatorial chemistry therapy.In some embodiments, chemotherapeutic agent
Agent (including combinatorial chemistry therapy) can be applied in combination with compound described herein.
Targeted therapies
In some embodiments, compound described herein is to use together with one or more targeted therapies.Targeting
Therapy constitutes the cancer cell proteins matter to imbalance and has the use of specific medicament.Some little targeted molecular therapy medicines lead to
Be often suddenly change in cancerous cell, process LAN or the inhibitor of enzymatic domain on other key proteins.Highlight
Example is tyrosine kinase inhibitor, and such as Axitinib, bosutinib, AZD2171, Dasatinib, Erlotinib, she replaces by horse
Buddhist nun, gefitinib, Lapatinib, lestaurtinib, Buddhist nun strangle for Buddhist nun, SU5416, Sorafenib, Sutent and Fan Deta
Buddhist nun, and cell cycle protein dependent kinase inhibitor, such as Avobenzene former times ground (Alvocidib) and Sai Lixibu
(Seliciclib).Monoclonal antibody therapy is another kind of strategy, and in this therapy, therapeutic agent is that specific bond is in cancerous cell table
The antibody on protein on face.Example includes the anti-HER2/neu antibody trastuzumab being typically used in breast carcinomaAnd the anti-CD 20 antibodies Rituximab being typically used in multiple B cell malignant disease and
Tositumomab.Other exemplary antibodies includes Cetuximab, Victibix, Herceptin, Ah coming organizes monoclonal antibody, shellfish cuts down list
Anti-, edrecolomab and gemtuzumab Ozogamicin Mylotarg CDP 771.Exemplary fusion proteins includes VEGF Trap and denileukin.In some embodiments
In, targeted therapies can be applied in combination with compound described herein.
Exemplary other therapeutic agent can also include EGF-R ELISA (EGFR) inhibitor, and the most western appropriate former times is single
Anti-, Victibix, gefitinib, Erlotinib, Buddhist nun's trastuzumab, horse trastuzumab, prick calamite monoclonal antibody (zalutumumab) or
Lapatinib.Resistance for EGFR inhibitor can become mesenchyme phenotype or mesenchyme phenotype to occur because of cells switch, and
Have EGFR sudden change and mesenchyme phenotype tumor can for EGFR inhibitor have lower sensitivity (see for example,
Sequist etc., (2011) Sci Transl Med.3:75;Buck etc., (2007) Mol Cancer Ther.6:532;
Thomson etc., (2008) Clin Exp Metastasis 25:843).
Exemplary other therapeutic agent may also include glutathione depletors, and such as L-butylthiamine acid-(S, R)-sulfoxide is sub-
Amine (BSO).
Exemplary other therapeutic agent can also include phosphoinositide 3-kinase (PI3K) inhibitor, such as perifosine,
De Laxibu (Idelalisib), BKM120, PX-866, IPI-145, NVP-BEZ235, GDC0941 and BAY 80-6946.
Exemplary other therapeutic agent may also include heat shock protein 90 (HSP90) inhibitor, such as geldanamycin, root
Red shell rhzomorph, 17-N-allyl amino-17-AAG (17AAG), lattice Buddhist nun are for cloth (ganetespib), 4-
(4-(2,3-dihydro-1,4-benzo dioxine-6-base)-5-methyl isophthalic acid H-pyrazole-3-yl)-6-ethyl resorcinol,
AUY922 (NVP-AUY922), BIIB021, STA9090, AT13387, NVP-BEP800 and SNX-2112 (PF-04928473).
Targeted therapies may also refer to the little peptide as " target-seeking equipment (homing device) ", and they can be combined in swollen
Cell surface receptor around tumor or affected extracellular matrix.If connected to the radioactive nucleus of these peptides (such as, RGD)
Element decays near cancerous cell, then this nucleic kills this cell the most at last.The example of this therapy includes
Immunotherapy
In some embodiments, compound described herein is to use together with one or more immunotherapies.Cancer
Immunotherapy refers to that the immune system being designed for inducing patient self is to one group of various therapeutic strategy of antineoplastic.For producing
Current methods for the immunne response of tumor includes BCG immunotherapy in the capsule of superficial bladder carcinoma, and uses interference
Element and other cytokine induce immunoreation in renal cell carcinoma and melanoma patients.
Allogeneic Hematopoietic Stem Cell Transplantation is regarded as a kind of form of immunotherapy, because the immunocyte of donor is frequent
Tumor will be attacked with Graft-versus-tumor response.In some embodiments, immunotherapy agents can be with described hereinization
Compound is applied in combination.
Hormonotherapy
In some embodiments, compound described herein is to use together with one or more hormonotherapies.Some
The growth of cancer can suppress by providing or blocking some hormone.The Common examples of hormone-sensitive tumor includes some class
The breast carcinoma of type and carcinoma of prostate.Removal or blocking-up estrogen or testosterone are often important additional treatment.In some cancer,
With Hormone agonists such as progestin administration may treatment on useful.In some embodiments, hormonotherapy medicament can be with
Compound described herein is applied in combination.
Nutrient limitation diet
In some embodiments, compound described herein is to be combined with one or more nutrient limitation diet to execute
With.Owing to cancerous cell relies on glucose to produce cellular energy, therefore reduce Fructus Vitis viniferae by carbohydrate restriction and protein
Sugar blood level can suppress the growth of certain cancers.In some cancer, nutrient limitation diet, such as heat restriction, fasting
And high fat diet, may be useful in treatment.In some embodiments, this nutrient limitation diet can with retouch herein
The compound stated is applied in combination.
Neural disorder
Compound described herein or compositions can be used for treatment or prevent from (such as, being exposed to by neuronal tissue's damage
Ischemia or anoxic event, wound or the nervous tissue of chronic neurodegenerative disease) Neuronal cell death that causes." neural
Unit's disease " be the sacred disease relevant to glutamate excitotoxicity or disease, such as by the god of such as apoplexy or ischemic event
The cerebral ischemia caused through event or anoxia.Can be neuroprotective is effectively provided, such as to prevent god with this compounds for treating
Amount through unit's cell death.
Compositions and route of administration
Compositions set forth herein includes compound set forth herein (such as compound described herein), and other
Therapeutic agent (if present), its amount is effective to realize the tune to disease or disease symptoms (include described herein those)
Joint.
Term " pharmaceutically acceptable carrier or adjuvant " refers to execute to experimenter together with compound provided herein
Carrier or adjuvant, and this carrier or adjuvant do not damage its pharmacological activity and when with the chemical combination that be enough to deliver therapeutic dose
When the dosage of thing is used nontoxic.
Pharmaceutically acceptable carrier, adjuvant or the medium that can be used in pharmaceutical composition provided herein include but not
It is limited to, ion-exchanger;Aluminium oxide;Aluminium stearate;Lecithin;Self-emulsifying drug delivery systems (SEDDS), such as d-alpha-tocopherol
Cetomacrogol 1000 succinate;Surfactant in pharmaceutical dosage form, as TWEEN Series (Tweens) or other be similar to
Polymeric delivery matrices;Serum albumin, such as human serum albumin;Buffer substance, such as phosphate;Glycine;Sorbic acid;Pyrusussuriensis
Acid potassium;The partial glyceride mixture of saturated vegetable fatty acid;Water;Salt or electrolyte, as protamine sulfate, disodium hydrogen phosphate,
Potassium hydrogen phosphate, sodium chloride, zinc salt, silica sol, magnesium trisilicate;Polyvinylpyrrolidone;Material based on cellulose;Poly-
Ethylene glycol;Sodium carboxymethyl cellulose;Polyacrylate;Wax;Polyethylene-polyoxypropylene block polymer;Polyethylene Glycol and sheep
Hair fat.Cyclodextrin, as α-, β-and gamma-cyclodextrin, or the derivant of chemical modification, such as hydroxyalkyl cyclodextrin, including 2-and 3-
HP-β-CD, or other derivant dissolved, it is also possible to favorably for strengthening the chemical combination of multiple formula described herein
The delivery of thing.
Pharmaceutical composition provided herein can with per os, parenteral, by suck spraying, partly, per rectum, per nasal,
Buccal, transvaginal or use via the storage tank implanted, preferably by Orally administered or used by injection.Medicine provided herein
Compositions can comprise nontoxic pharmaceutically acceptable carrier, adjuvant or the medium of any routine.In some cases, preparation
PH value can be adjusted with pharmaceutically acceptable acid, alkali or buffer, deliver strengthening the compound prepared or its
The stability of form.As used herein, this term parenteral includes subcutaneous, Intradermal, intravenous, intramuscular, intraarticular, tremulous pulse
In, in intrasynovial, breastbone, in sheath, intralesional and intracranial injection or infusion techniques.
Pharmaceutical composition can be to be the form of sterile injectable prepared product, such as aqueous or the oiliness of sterile injectable
Suspension.Dispersion or wetting agent that this suspension can be suitable for according to technology as known in the art, use (e.g., such as, are told
Temperature 80) and suspending agent prepare.Sterile injectable prepared product can also is that at nontoxic parenteral acceptable diluent or molten
Sterile injectable solution in agent or suspension, such as the solution 1, in 3-butanol.The acceptable matchmaker that can use
It is situated between and solvent has mannitol, water, Ringer's mixture (Ringer ' s solution) and isotonic sodium chlorrde solution.Additionally, routinely
Use aseptic fixed oil as solvent or suspension media.For this purpose, the fixedness of any gentleness can be used
Oil, including monoglyceride or two glyceride of synthesis.Fatty acid (such as oleic acid and glyceride ester derivatives thereof) can be used on injection
In preparation, natural pharmaceutically acceptable oil (such as olive oil or Oleum Ricini), especially their polyoxyethylated versions, also
It is such.These oil solutions or suspension can also contain long-chain alcohol diluents or dispersant, or carboxymethyl cellulose or conventional
Prepare pharmaceutically acceptable dosage form (as emulsion with or suspension) similar dispersant.Purpose for preparation, it is also possible to
Use other the conventional surfactant being usually used in preparing pharmaceutically acceptable solid, liquid or other dosage form, such as tween
Series or this dish series (Spans), and/or other similar emulsifying agent or bioavailability reinforcing agent.
Pharmaceutical composition provided herein can be any oral acceptable dosage form oral administration, this dosage form include but
It is not limited to, capsule, tablet, emulsion and waterborne suspension, dispersion liquid and solution.In the case of the tablet Gong orally using,
Conventional carrier includes lactose and corn starch.Typically it is also added with lubricant, such as magnesium stearate.For with capsule form per os
Clothes are used, and the diluent being suitable for includes lactose and the corn starch being dried.When waterborne suspension and/or emulsion oral administration
Time, can be suspended or dissolved in active component combining in the oil phase of emulsifying agent and/or suspending agent.If desired, may be used
To add some sweeting agent and/or flavoring agent and/or coloring agent.
Pharmaceutical composition provided herein can also be used for the suppository form for rectal administration.These compositionss can be passed through
Being mixed with the nonirritant excipient being suitable for by compound provided herein and prepare, this excipient is at room temperature solid, but
It is liquid under rectal temperature, and therefore will melt in the rectum and discharge active component.These materials include but not limited to,
Cocoa butter, Cera Flava and Polyethylene Glycol.
When desired treatment relates to the region or the organ that are easily accessible to by local application, medicine provided herein
The local application of compositions is applicable.For being applied to skin partly, pharmaceutical composition should suspend with containing or dissolve
The ointment being suitable for of the active component in carrier configures together.Carrier bag for the local application of compound provided herein
Include but be not limited to, mineral oil, Albolene, white vaseline, propylene glycol, polyethylene glycol oxide polyoxypropylene compound, emulsifying
Wax and water.As an alternative, this pharmaceutical composition can be suspended or dissolved in in the carrier of applicable emulsifying agent with containing
Reactive compound be suitable for washing liquid or emulsifiable paste configure together.The carrier being suitable for includes but not limited to, mineral oil, anhydrosorbitol
Sugar alcohol monostearate, polysorbate60, spermaceti ester type waxes, cetearyl alcohol, 2-octyl dodecanol, benzyl alcohol and water.Herein
The pharmaceutical composition provided by rectal suppository formulation or can also be applied to lower intestinal tract with applicable enema preparation partly.
In transdermal patch is also included within partly.
Pharmaceutical composition provided herein can be used by nasal aerosol or suction.These compositionss are according to medicine
In formulation art prepared by widely-known technique, and can use benzyl alcohol or other anticorrosion being suitable in normal saline
Agent, the enhancing absorption enhancer of bioavailability, fluorocarbon and/or other solubilizing agent as known in the art or dispersion
Agent, is prepared as solution.
When compositions provided herein comprises compound and one or more other treatments of multiple formula described herein
During the combination of agent or preventive, this compound existed should be single medication side with the dosage level of this other medicament
In case between about the 1% to 100% of usual application dosage, between the most about 5% to 95%.This other medicament can be made
A part for multiple dose scheme is used dividually with compound provided herein.As an alternative, these medicaments can be as list
A part for one dosage type low temperature, is mixed together in single compositions with compound provided herein.
Compound described herein can such as pass through intravenous, intra-arterial, subcutaneous, intraperitoneal, intramuscular or subcutaneous injection,
Or per os, buccal, per nasal, across mucosa, use with ophthalmically acceptable prepared product form partly, or used by suction, dosage range from
Per kilogram of body weight about 0.5 is to about 100mg, alternately, dosage between every dose of 1mg and 1000mg, every 4 to 120 hours, or root
Use according to the needs of certain drug.Methods herein covers uses the compound of effective dose or compound composition to realize
Effect that is desired or that state.Typically, pharmaceutical composition provided herein will the most about 1 time to about 6 times, or alternative
Ground, uses with continuous infusion.This using can be used as chronic or acute therapy.Can be combined to produce single with carrier material
The amount of the active component of dosage form will change with the host treated and specific application pattern.Typical prepared product will contain about
The reactive compound (w/w) of 5% to about 95%.As an alternative, these prepared products contain the active ingredient of about 20% to about 80%
Thing.
May require than those lower or higher dosage set forth above.Concrete dosage for any particular patient
Many factors is will depend upon which, including the activity of the particular compound used, age, body weight, general health disease with therapeutic scheme
Suffer from, sex, diet, time of application, discharge rate, drug regimen, the order of severity of disease, illness or symptom and the course of disease, patient
Tendentiousness to disease, illness or symptom, and the judgement for the treatment of physician.
After the illness of patient is improved, if necessary, it is possible to the dimension of compound provided herein, compositions or combination
Hold dosage to use.Subsequently, with the change of symptom, can by applied dose or frequency or both, be reduced in these symptoms
The level of the illness of this improvement is kept in time being relieved to desired level.But, patient may be required for disease symptoms
Any recurrence carries out long-term intermittent treatment.
Patient selects and monitoring
Compound described herein can suppress transglutaminase.Therefore, can by firstly evaluate patient and/or experimenter with
Determine that this experimenter, the need of suppression transglutaminase, selects patient and/or experimenter to use chemical combination described herein
Thing is treated, if this experimenter is confirmed as needing glutamine enzyme level, then use described herein to this experimenter
Compound.
Method as known in the art can be used, such as by measuring existence and/or the activity of patient's GLN enzyme,
It is evaluated as experimenter needing glutamine enzyme level.In some embodiments, to the activity of cancer GLN enzyme and/
Or level is estimated.
Can such as the patient to receiving compound described herein that improves for illness and/or ill effect supervise
Survey.The improvement of patient's illness can such as be commented by growth, the shortage of growth or disappear of monitoring cancer (such as tumor)
Estimate.In some embodiments, use the assessment of radioactivity determination or hemolysis parameters that patient is estimated.
Patient and/or experimenter can be selected in the following manner to use compound described herein to treat:
Optionally obtain Patient Sample A;Assess this sample to determine whether this sample is characterised by i) relatively low compared with reference standard E-
Cadherin expression, ii) Vimentin level higher compared with reference standard, and/or iii) and reference standard
Compare pyruvate carboxylase expression that is relatively low or that reduce;And if it is determined that this patient has compared with reference standard relatively low
CAM 120/80 expression, or Vimentin level higher compared with reference standard, then with described hereinization
Compound is used to this patient.
In some embodiments, by the expression of CAM 120/80 compared with reference standard, wherein this reference mark
Standard is the expression of CAM 120/80 in epithelial cell, as any one in documents below is characterized: (Yauch etc.,
(2005) Clin Cancer Res 11:24;Savagner etc., (2010) Ann Oncol.21 (supplementary issue 7): vii89;Thiery
Deng, (2002) Nature Reviews Cancer 2 (6): 442).In some embodiments, compared with this reference standard, E-
The expression of cadherin is relatively low, reduce or do not exist.In some embodiments, the expression of CAM 120/80 is logical
The level crossing the RNA to coding CAM 120/80 is estimated measuring.In some embodiments, the expression of CAM 120/80
Level is that the protein expression level by CAM 120/80 is assessed.In some embodiments, the expression of CAM 120/80
Level is lower than this reference standard by least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80% or
90%.In some embodiments, the expression of CAM 120/80 has at least compared with this reference standard in terms of expression
1.5, the reduction of 2,5,10,15,20,25,50,75,100 times.
In some embodiments, by the expression of Vimentin compared with reference standard, wherein this reference standard
It is Vimentin expression in epithelial cell, as below with reference in document, any one characterizes: (Yauch etc.,
(2005) Clin Cancer Res 11:24;Savagner etc., (2010) Ann Oncol.21 (suppl 7): vii89;
Thiery etc., (2002) Nature Reviews Cancer 2 (6): 442).In some embodiments, the table of Vimentin
The level of reaching is by being estimated measuring to the level of the RNA of coding waveforms albumen.In some embodiments, Vimentin
Expression be that the protein expression level by Vimentin is assessed.In some embodiments, the table of Vimentin
The level that reaches is higher than this reference standard by least 5%, 10%, 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%
Or 90%.In some embodiments, the expression of Vimentin has at least compared with this reference standard in terms of expression
1.5, the increase of 2,5,10,15,20,25,50,75,100 times.
In some embodiments, the expression of pyruvate carboxylase is relatively low or reduction compared with reference standard, wherein
This reference standard is pyruvate carboxylase expression in epithelial cell, as below with reference in document, any one characterizes
: (Yauch etc., (2005) Clin Cancer Res 11:24;Savagner etc., (2010) Ann Oncol.21 (suppl
7):vii89;Thiery etc., (2002) Nature Reviews Cancer 2 (6): 442).In some embodiments, acetone
The expression of acid carboxylase is higher or increase compared with this reference standard.In some embodiments, pyruvate carboxylase
Expression is by being estimated measuring to the level of the RNA of encoding pyruvate carboxylase.In some embodiments, third
The expression of keto acid carboxylase is that the protein expression level by pyruvate carboxylase is assessed.In some embodiments
In, the expression of pyruvate carboxylase is higher than this reference standard by least 5%, 10%, 15%, 20%, 25%, 30%, 40%,
50%, 60%, 70%, 80% or 90%.In some embodiments, the expression of pyruvate carboxylase and this reference standard
Compare the increase having at least 1.5,2,5,10,15,20,25,50,75,100 times in terms of expression.
Patient Sample A
Term " Patient Sample A ", " Samples subjects " with " sample " used interchangeably herein.Patient Sample A can be group
Knit, or body fluid, or health product.Tissue sample can include that fix, paraffin-embedded, the fresh or sample of freezing.Citing
For, tissue sample can include biopsy, cheek swab.Example organization include lung, breast, brain, nervous tissue, kidney,
Ovary, thyroid, pancreas, colon, prostate, lymph node, skin, hair follicle and fingernail.Exemplary sample includes deriving from entity
The sample of tumor.Exemplary body fluid includes blood, blood plasma, urine, lymph fluid, tear, perspiration, saliva, seminal fluid and cerebrospinal fluid.
Exemplary health product includes expired gas.
This tissue, fluid or product can take out from patient and be analyzed.Assessment can include following one or more:
Carry out the analysis to this tissue, fluid or product;Require the analysis of this tissue, fluid or product;Require from this tissue, fluid or
The result that the analysis of product obtains;Or receive the result that the analysis from this tissue, fluid or product obtains.
Can be for the expression of gene described herein (such as, CAM 120/80, Vimentin, pyruvate carboxylase)
This sample tissue, fluid or product are analyzed.Can be for protein described herein (such as, CAM 120/80, waveform
Albumen, pyruvate carboxylase) expression this sample tissue, fluid or product are analyzed.Can be for the letter of preliminary election
(such as, epithelium is to mesenchyme transition pathway, CAM 120/80 approach, Vimentin approach or acetone for number approach or phenotype approach
Acid carboxylase approach) a kind of gene or the gene expression dose of several genes this sample tissue, fluid or product are carried out
Analyze further.Can (such as epithelium be to mesenchyme transition pathway, CAM 120/80 for the signal pathway of preliminary election or phenotype approach
Approach, Vimentin approach or carboxylase enzymatic pathway) a kind of protein or the protein expression level of multiple proteins
This sample tissue, fluid or product are further analyzed.
The method of assessment sample
The expression of gene described herein (such as, CAM 120/80, Vimentin and pyruvate carboxylase) can make
Method with the multiple well-known expression transcribing molecule, gene, protein, mRNA, genomic DNA or cDNA for detection
In any one be evaluated.Gene expression can pass through the measurement of genetic transcription thing (such as, mRNA), by the albumen of translation
The amount of matter measure or measure by the measurement of gene product activity or monitor;Any of which all can use this area
Standard technique known to the skilled person is measured.The limiting examples of these methods includes nucleic acid hybridization, nucleic acid reverse transcription
Method, nucleic acid amplification, immunization method, protein purification method, protein function or activation measurement for protein detection.
CAM 120/80
CAM 120/80 gene is positioned on human chromosome 16.CAM 120/80 is that the classical calcium of cadherin superfamily glues egg
In vain.Coded CAM 120/80 is Ca-dependent cell-cell adherence glycoprotein, comprises five extracellular Ca2+ mucin weights
Again, cross-film district and the cytoplasmic tail of high conservative.Sudden change in this gene with include gastric cancer, breast carcinoma, colorectal carcinoma,
Thyroid carcinoma and ovarian cancer are correlated with in interior cancer.Expection CAM 120/80 function forfeiture by increase propagation, invasion and attack and/or
Shift and contribute to cancer progression.The ectodomain of this protein has mediated the antibacterial adhesion to mammalian cell, cell
Matter domain is required by internalization.The CAM 120/80 transcript variant identified is drawn by the sudden change of consistent splice site
Rise.
Vimentin
Vimentin dna is positioned on human chromosome 10, the member of coding intermediate filament protein family.Median fiber, even
Together form the cytoskeleton of cell with micro-pipe and actin filament, it contributes to maintaining cell shape and cytoplasmic complete
Whole property, and stablize cytoskeleton interaction.Vimentin also acts as mediated immunity response, controls low density lipoprotein, LDL source
Cholesterol transport the effect of esteratic site from lysosome, and act as adhering to, migrating and involved in cell signalling
And the organizer of multiple key proteins.
Pyruvate carboxylase (PC)
PC gene is positioned on human chromosome 11, coded protein pyruvate carboxylase, and this enzyme catalysis carboxylase becomes grass
Ethyl acetoacetic acid.This organized enzyme is to be arranged in the tetrahedral homotype tetramer, and it is only located in mitochondrial matrix.Pyruvate carboxylase is joined
With multiple cell processes, generate including glyconeogenesis, fat, insulin secretion and the synthesis of neurotransmitter glutamate.In this gene
Sudden change is associated with pyruvate carboxylase deficiency.Identify and there are different 5 ' UTR but encoded replacing of this same protein
Transcript variant for property montage.
Nucleic acid molecules
Method described herein can relate to based on corresponding to gene described herein (such as CAM 120/80, Vimentin,
Pyruvate carboxylase) the nucleic acid of separation, the mRNA level in-site of such as CAM 120/80, the mRNA level in-site of Vimentin, acetone acid
The mRNA level in-site of carboxylase, the expression of gene described herein to sample evaluating.As used herein, term " nucleic acid " or " nucleic acid
Molecule " it is intended to include DNA molecular (such as, cDNA or genomic DNA) and RNA molecule (such as, mRNA) and use nucleotide
The analog of DNA or RNA that analog produces.This nucleic acid molecules can be strand or double-strand.
" separation " nucleic acid molecules is the separate core of other nucleic acid molecules present in the natural origin with this nucleic acid molecules
Acid molecule." separation " nucleic acid molecules can be free of and adjoins this core natively in obtaining the genomic DNA of organism of this nucleic acid
The sequence (such as the sequence of coded protein) of acid (that is, being positioned at the sequence at 5 ' and 3 ' ends of this nucleic acid)." separation " nucleic acid divides
Son, such as mRNA, can be substantially free of other cell material in the cell or tissue source obtaining this nucleic acid or other pollutes
Property protein.
Nucleic acid molecules described herein can use standard molecular biological technique and well known by persons skilled in the art count
In recording according to storehouse, available sequence information separates.Use all or part of of these nucleotide sequences, standard can be used miscellaneous
Hand over and clone technology (such as, compile such as Sambrook etc., Molecular Cloning:A Laboratory Manua, second edition,
Cold Spring Harbor Laboratory Press, described in Cold Spring Harbor, NY, 1989) separate this
The nucleic acid molecules that literary composition describes.
Nucleic acid molecules described herein can use cDNA, mRNA or genomic DNA conduct according to standard PCR amplification technology
Template and suitable oligonucleotide primers expand.The nucleic acid molecules thus expanded can be cloned in suitable carrier, and
Characterized by DNA sequence analysis.Additionally, all or part of oligonucleotide corresponding to nucleic acid molecules can pass through standard
Synthetic technology, prepares for example with automatization's DNA synthesizer.
The nucleic acid molecules separated can comprise such nucleic acid molecules, and it has and the nucleic acid corresponding to gene described herein
Nucleotide sequence, or with coding corresponding to the nucleoside of nucleotide sequence complementary of the nucleic acid of the protein of gene described herein
Acid sequence.Substantially complementary with the nucleotide sequence that the nucleic acid molecules of given nucleotide sequence complementary is given with this make it
The nucleic acid molecules of stable duplex can be consequently formed with this given nucleotide sequence hybridization.
Nucleic acid molecules described herein can only comprise a part for nucleotide sequence.These nucleic acid molecules can be used for example as probe
Or primer.Probe/primer can be the oligonucleotide of one or more generally purification.Sequence based on nucleic acid molecules described herein
The probe of row can be used for detecting the transcript corresponding to gene described herein or genome sequence.This probe can comprise labelling base
Group, such as radiosiotope, fluorescent chemicals, enzyme or enzyme cofactor.These probes can be used as the one of diagnostic test reagent box
Part, this test kit is as by surveying the level of the nucleic acid molecules encoding this protein in the cell sample of patient
Amount, such as detection mRNA level in-site identifies the cell or tissue expressing this protein.
The method of detection gene expression
The method of detection and/or quantitatively genetic transcription thing (such as mRNA or the cDNA being generated by) may include but be not limited to
Southern blotting technique analysis, rna blot analysis, polymerase chain reaction (PCR) are analyzed and probe assay.Detection and/or quantitatively genetic transcription
The method of thing (such as mRNA or the cDNA being generated by) may include but be not limited to method based on hybridization, such as with to this gene
The hybridization that transcript (such as mRNA or the cDNA being generated by) special probe is carried out.Genetic transcription thing (such as mRNA or by
Its cDNA produced) level can be by by this sample, or this mRNA or the cDNA that is generated by, or the sample expanded by it
It is applied to nucleic acid microarray or chip array is measured.
The level of genetic transcription thing (such as mRNA or the cDNA being generated by) can be by based on polymerase chain reaction (PCR)
Method, such as quantitative PCR, quantitatively in real time PCR, real-time PCR, reverse transcription PCR, Real time RT-PCR are measured.Gene
The level of transcript (such as mRNA or the cDNA being generated by) can be by method based on order-checking, and such as quantitatively RNA order-checking comes
It is measured.
The level of genetic transcription thing (such as mRNA) can be determined by original position as known in the art or in vitro method.Right
In in vitro method, the available separation being not directed to mRNA and any RNA isolation technics of selecting are from sample, such as from sample
Cell purification RNA (see, e.g., Ausubel etc. to compile, Current Protocols in Molecular Biology, John
Wiley&Sons,New York 1987-1999).It addition, technology well known to the skilled person can be used, as such as
The single stage RNA separating technology of bur Xin Siji (Chomczynski) (1989, United States Patent (USP) No.4,843,155) is the most right
A large amount of tissue samples are treated.For in-situ method, mRNA is before testing without separating from cell.These sides
In method, known Histological method can be used to prepare/process cell or tissue sample.This sample can be fixed on holder subsequently
On, then contacting with probe, this probe can be with the mRNA hybridization of coding genes of interest transcript.
Mensuration can absolute expression levels based on genetic transcription thing (such as mRNA), normalized expression or relative table
Reach level.Can by by the expression of genetic transcription thing and the another kind of gene stably expressed (such as constitutive expression
House-keeping gene) expression compare, its absolute expression levels is corrected, by expression normalization.For returning
One gene being suitable for changed includes house-keeping gene, such as histone H3 gene or actin gene.This normalization allows one
Individual sample and another sample, the first sample such as obtained from patient with from this same patient (such as from another tissue or
When different time points) the second sample of obtaining;Or between the sample of separate sources, such as from the trouble of a patient
Person's sample compares with the expression of the Patient Sample A from another one patient.
The expression provided can be as relative expression levels.This relative expression levels can be by by this genetic transcription thing
The absolute expression levels of (such as mRNA) relatively determines compared with reference standard.This reference standard may be included in genotype or phenotype
The expression of the genes of interest transcript in the sample determined.This reference standard can be to be epithelium in genotype or Phenotypic characterization
The expression water of the genes of interest transcript (such as, CAM 120/80, Vimentin, pyruvate carboxylase) in the cell of cell
Flat.Epithelial cell can be as characterized in the following documents any one: (Yauch etc., (2005) Clin Cancer Res
11:24;Savagner etc., (2010) Ann Oncol.21 (suppl 7): vii89;Thiery etc., (2002) Nature
Reviews Cancer 2(6):442)。
Can at least two point in time measurement genetic transcription described herein things (such as, CAM 120/80, Vimentin,
Pyruvate carboxylase) expression to determine whether there occurs the change of expression.For example, can be with described herein
Compounds for treating before and after, or survey at one or more time points during treating by compound described herein
Amount expression.If it find that this expression reduce, the expression of such as CAM 120/80 reduce compared with reference standard and/or
The expression of Vimentin increase compared with reference standard, then can give with controlling that compound described herein is carried out to experimenter
Treat.This reference standard can be by the expression of the genes of interest transcript in the epithelial cell characterized.Epithelial cell can lead to
Cross method as known in the art, such as, as characterized in the following documents any one: (Yauch etc., (2005) Clin
Cancer Res 11:24;Savagner etc., (2010) Ann Oncol.21 (suppl 7): vii89;Thiery etc., (2002)
Nature Reviews Cancer 2(6):442)。
Protein
Method described herein can relate to based on corresponding to gene described herein (such as CAM 120/80, Vimentin,
Pyruvate carboxylase) the protein of separation, the protein level of such as CAM 120/80, the protein level of Vimentin,
The protein level of pyruvate carboxylase, the expression of gene described herein to sample evaluating.This may also comprise it biological alive
Property part, variant, hypotype or the assessment of splice variant.Can use known to those skilled in the art by suitable purification schemes
Standard protein purification technique, from sample, separate the natural polypeptides corresponding to destination protein matter.
" separation " or " purification " protein or its biologically-active moiety are substantially free of the cell obtaining this protein
Or the cellular material in tissue-derived or other contaminative protein.Term " generally without cellular material " includes protein
With the cellular component of the cell therefrom isolating this protein prepared by separate protein.The biologically-active moiety of polypeptide can include
Comprise the aminoacid sequence of aminoacid sequence that is the most consistent with the aminoacid sequence of this protein or that derive from this protein
Polypeptide, these polypeptide include the aminoacid more less than full length protein, and show corresponding full length protein at least one
Activity.Typically, biologically-active moiety comprises domain or the motif of at least one activity with respective egg white matter.
The method of detection protein expression
The expression of protein or polypeptide can arbitrary by multiple means well known to the skilled person
Plant and carry out detection with quantitative.Detection and/or quantitative protein described herein or polypeptide (such as, CAM 120/80, waveform egg
In vain, pyruvate carboxylase) method may include but be not limited to, biochemical method, such as electrophoresis, capillary electrophoresis, efficient liquid phase
Chromatography (HPLC), thin layer chromatography (TLC), super diffusion chromatography etc.;Or different immunoassays, such as fluid or gel
Precipitation, immunodiffusion (unidirectional or two-way), immunoelectrophoresis, radioimmunoassay (RIA), enzyme-linked immunosorbent assay
(ELISA), the cell sorting of immunofluorescence assay, western blot, immunohistochemistry, in situ hybridization, fluorescence-activation
(FACS) etc..Technical staff can easily use known protein/antibody detection method to be used for determining whether cell expresses
Protein described herein or polypeptide.
Protein or polypeptide can use immunoassay to detect.As used herein, immunoassay include utilizing specificity
It is incorporated into the mensuration of the antibody of protein or polypeptide.Immunoassay can be tied by the specificity of detection protein or polypeptide and antibody
Incompatible sign, from use other physically or chemically to separate, targeting and quantitatively this polypeptide different.This polypeptide can use multiple
Generally acknowledge immunity combine measure any one detect and/or quantitatively (see, e.g., United States Patent (USP) No.4,366,241;4,
376,110;4,517,288;And 4,837,168).About the commentary of general immunoassay, referring further to Asai (1993) Methods
In Cell Biology, volume 37: Antibodies in Cell Biology, Academic Press, Inc.New
York;Stites and Terr (1991) Basic and Clinical Immunology, the 7th edition.For detecting and/or quantitative
The immunoassay of protein or polypeptide can use various ways well known to the skilled person.
Can conjugated protein or the antibody of polypeptide, such as corresponding to protein described herein or polypeptide (such as, E-calcium
Mucin, Vimentin, pyruvate carboxylase) the antibody with detectable label (labelling directly or indirectly), available
In detecting this protein or polypeptide.Antibody can be polyclone or monoclonal.Complete antibody, or its fragment can be used, such as
Fab or F (ab')2.For probe or antibody, term " labelling " is intended to by by detectable material and this probe
Or antibody coupling (i.e., physically connect) and the probe that carries out or the direct labelling of antibody, and by with directly labelling
Another kind of reagent reacting and the probe that carries out or the indirect labelling of antibody.The example of indirect labelling includes using fluorescently-labeled
Two antibody test first antibodies, and with biotin, DNA probe is carried out end labelling so that it can use fluorescently-labeled chain
Mould Avidin detects.This antibody can be also labelling (the most radiolabeled, chromophore label, fluorogen labelling or
Enzyme labelling) antibody.Use antibody derivatives, such as with substrate or with protein-ligand to (such as biotin-strepto-is affine
Element) protein or the antibody that combines of part, or the antibody height structure changes territory etc. of antibody fragment, such as single-chain antibody, separation, should
Antibody derivatives specific bond in protein described herein, such as CAM 120/80, Vimentin, pyruvate carboxylase, as
By corresponding to protein described herein or the gene of polypeptide (such as CAM 120/80, Vimentin, pyruvate carboxylase)
Protein coded by the open reading frame of transcript, or experienced by its normal post translational modification all or part of this type of
Protein or polypeptide.
Protein from cell can use technology well known to the skilled person to separate.The albumen used
Matter separation method can for example, Harlow and Lane (Harlow and Lane, 1988, Antibodies:A Laboratory
Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York) in retouched
Those stated.
Expression can provide as relative expression levels.This relative expression levels can be by by the absolute table of this protein
The level that reaches relatively determines compared with reference standard.Purpose egg in the sample that this reference standard may be included in genotype or phenotype determines
The expression of white matter.This reference standard can be destination protein matter (example in genotype or cell that Phenotypic characterization is epithelial cell
As, CAM 120/80, Vimentin, pyruvate carboxylase) expression.Epithelial cell can pass through side as known in the art
Method characterizes, such as, as described in any one in documents below: (Yauch etc., (2005) Clin Cancer Res 11:
24;Savagner etc., (2010) Ann Oncol.21 (suppl 7): vii89;Thiery etc., (2002) Nature Reviews
Cancer 2(6):442)。
Protein described herein or the expression water of polypeptide (such as, CAM 120/80, Vimentin, pyruvate carboxylase)
Flat can at least at two point in time measurement to determine whether there occurs the change of expression.For example, can be with retouching herein
Before and after the compound stated is treated, or one or more time during treating by compound described herein
Point in time measurement expression.If it find that this expression decreases, the expression of such as CAM 120/80 and reference standard
Compare reduction and/or expression increase compared with reference standard of Vimentin, then can give with described herein to experimenter
The treatment that compound is carried out.
Test kit
There is also described herein test kit, these test kits include measuring gene described herein, and (such as, E-calcium glues egg
In vain, Vimentin, pyruvate carboxylase) the means of gene expression dose.For example, this test kit can include can with this
The examination that the gene expression product of the gene (such as, CAM 120/80, Vimentin, pyruvate carboxylase) that literary composition describes interacts
Agent.This test kit can include multiple can be with several genes described herein (such as, CAM 120/80, Vimentin, acetone acid
Carboxylase) gene expression product interact reagent.This reagent may include but be not limited to, antibody, Multiple Antibodies, oligonucleoside
Sour or multiple oligonucleotide.This gene expression product may include but be not limited to, the molecule transcribed, RNA molecule, polypeptide, protein,
Genomic DNA or cDNA.
This test kit the most optionally includes the reagent for carrying out mensuration described herein.For example, this test kit
Can include buffer agent, solvent, stabilizer, preservative, purification column, detectable and enzyme, they are probably and separate from Patient Sample A
Nucleic acid, such as, expand sample by qRT-PCR, and sample be applied to reagent described above, or from experimenter's sample
Product separation protein and sample is applied to necessary to reagent described above;Or for Samples subjects directly should
Reagent for reagent described above.Test kit may also include the positive and negative control sample, such as, compare nucleic acid samples (example
As, from non-oncological patients or non-tumor tissue sample or the experimenter not accepting treatment of cancer or for experimenter
Sample carries out the nucleic acid samples of other test sample tested simultaneously).Test kit may also include illustrative material, and this material can provide
Relevant collect and process Patient Sample A, these samples are applied to the finger that gene expression dose measures and explains measurement result
Lead.
The component of test kit can provide in any form, such as liquid, dry, semiarid or lyophilized form, or
The form stored under lyophilisation condition.Typically, the component of test kit is to provide in sterile form.When reagent provides molten at liquid
Time in liquid, this liquid solution is generally aqueous solution, such as aseptic aqueous solution.When reagent provides in a dry form, generally pass through
Add the solvent being suitable for realize rebuilding.This solvent of such as sterile buffer optionally provides in this test kit.
This test kit can include a kind of or multiple container, for the examination of dress concentration be applicable to gene expression dose measures
Agent box component, or with the description about the dilution in this mensuration.This test kit can comprise the list for these mensuration components
Only container, allotter or compartment, and information material.For example, positive and negative control sample can be included in bottle or
In bottle, the most compatible grader can be sealed in aseptic plastic packaging, and information material can be included in plastic bushing
Or in bag.This test kit can include the container that multiple (such as, a bag) is single, each comprises one or more units of reagent
Form (such as, for once measuring).The container of these test kits can be bubble-tight and/or waterproof.This container can be for
Purposes is marked.
This test kit can include the information material for carrying out and explain this mensuration.This test kit may also provide relevant at what
The guidance of the result of this mensuration is reported at place, such as, remove therapeutic community or health care provider.This test kit can include for reporting
Accuse the form of gene activity measurement result described herein, and relevant these forms or other relevant information of whither sending
Address and contact details, or the relevant URL (unified resource of report result in online database or application on site (such as, app)
Localizer) address.In another embodiment, this information material can include the result about depending on this mensuration, and whether patient
The guidance with anticancer stem cell agent therapy should be accepted.
The information material of these test kits is not limited to its form.In many cases, information material (such as description)
It is to provide with the form of leaflet, such as printed text, picture and/or photo, such as labelling or printed sheet.But, provided
Information material can be also other form, such as computer readable-material, records a video or records.The information material of this test kit can be contact
Information, such as physical address, e-mail address, webpage or telephone number, wherein the user of this test kit can obtain correlation gene work
Property measure and/or the substantive information of its application in method described herein.This information material can be with multiple format
Any combination provides.
Samples subjects may be provided to measure supplier, such as ISP (such as the third-party institution) or medical services
Supplier, it will be assessed sample in mensuration and provide reading result.For example, measure supplier and can receive sample from experimenter
Product, such as tissue sample, or blood plasma, blood or blood serum sample, use described herein mensuration to assess this sample, and determine that this is subject to
Examination person is to accept with the candidate of inhibitor for treating as described herein.This mensuration supplier may be notified that health care provider should
Experimenter is the candidate with inhibitor for treating as described herein, and uses inhibitor described herein to this candidate.
The result that this mensuration supplier can assess, and optionally about the one or many in diagnosis, prognosis or appropriate therapy selection
Kind result with any applicable form, as by mail, or electronically, or be supplied to such as medical by online database
ISP, or patient, or insurance company.The information collected by this mensuration supplier and provide can be stored in data base.
Embodiment
Embodiment A
In the present embodiment, measured the enzymatic activity of transglutaminase by the endpoint determination of coupling.By glutamine and
Phosphate is each with equal to Km and AC50Concentration be supplied to GAC, and adjust GAC concentration to obtain linear response, continue 60 points
Clock.Produced glutamate, Glu is changed into 2-OG by the glutamte dehydrogenase of kinetics excess.NAD is set to by this second step
2X Km, because the NAD of excess is inhibition.But, the third conjugate enzyme diaphorase of kinetics excess reclaims from NADH
NAD is so that the concentration of NAD keeps constant during the time-histories of this mensuration.Diaphorase, also supplies with kinetics excess, it
The NADH produced by GDH is aoxidized back NAD, is reduced into the resorufin of high fluorescence with "diazoresorcinol" simultaneously.Stopping being somebody's turn to do with SDS
After mensuration, measure resorufin by Ex544/Em590.Reducing of signal indicates the suppression of certain component in coupled enzymatic system.
Hit thing (hit) likely is screened (counterscreen) only for GDH/ diaphorase is counter, to remove second
The hit thing of the coupled enzymatic system in mensuration.
1. material
2. buffer
2X buffer (300mM NaCl, 100mM HEPES pH 8.5,0.1%BSA, 0.5mM EDTA, 100mM phosphoric acid
Sodium pH 8.5)
(1X buffer Final concentration, containing 13mM glutamine, 100 μMs of "diazoresorcinol"s, 50 μ g/ml cardiac muscles for 5X substrate mixture
Yellow enzyme)
(1X buffer Final concentration, containing 0.875 μ g/ml GAC, 1.56mM NAD, 6.25 units/ml for 1.2X enzymatic mixture
GDH)
Termination mix (ddH26%SDS in O)
Response procedures
1. add the 1 μ l 100%DMSO containing compound
2. add 40 μ l enzymatic mixtures and at room temperature hatch 60 minutes
3. add 10 μ l substrate mixture to start reaction
4. terminate reaction with the 6%SDS of 25 μ l and read Ex544Em 590
Embodiment B:
In the present embodiment, by the endpoint determination of coupling, the conjugate enzyme of compound suppression transglutaminase HTS method is surveyed
The potentiality determining system are tested, and this system includes glutamte dehydrogenase and diaphorase.Glutamate, Glu is supplied to Km
GDH, then carries out reducing deacylated tRNA amine to produce 2OG.NAD is fed to this system with 2X Km, and by the activity of diaphorase
Monitor its conversion to NADH.Diaphorase is to be supplied to GDH with a large amount of kinetics excess, it NADH is converted back into NAD with
Make NAD level keep constant in the reaction, resazurin reduction is become the resorufin of high fluorescence simultaneously.This survey is being terminated with SDS
After Ding, measure resorufin by Ex544/Em590.Reducing of signal indicates the suppression of certain component in coupled enzymatic system.
3. material
4. buffer
2X buffer (300mM NaCl, 100mM HEPES pH 8.5,0.1%BSA, 0.5mM EDTA, 100mM phosphoric acid
Salt pH 8.5)
2X substrate mixture (1X buffer Final concentration, 40 μMs of "diazoresorcinol"s, 1.8mM glutamic acid, 20 μ g/ml diaphorases)
10X NAD mixture (1X buffer Final concentration, 12.5mM NAD)
(1X buffer Final concentration, by for the most linear measured GDH enzyme for 2.5X enzymatic mixture;Such as, as retouched herein
State 0.05 unit/ml to obtain the final concentration of 0.02 unit/ml).
Response procedures
1. add the 1 μ l 100%DMSO containing compound
2. add 20 μ l enzymatic mixtures and at room temperature hatch 60 minutes
3. add 5 μ l NAD mixture
4. add 25 μ l substrate mixture to start reaction
5. terminate reaction with the 6%SDS of 25 μ l and read Ex544Em 590
Such as pass through the mensuration described in embodiment, the energy of compound described herein suppression transglutaminase can be tested
Power.For succinctly, the IC of test during the inhibitory activity of these compounds is expressed as the mensuration of embodiment A or embodiment B in table 150。
The data of exemplary compounds are shown below in table 2.As shown, " A " refers to IC50< the glutamine enzyme level of 100nM
Agent." B " refers to IC50Glutamine enzyme inhibitor between 100nM and 500nM." C " refers to IC50Between 500nM and 1000nM
Glutamine enzyme inhibitor." D " refers to IC50Glutamine enzyme inhibitor between 1 μM and 2 μMs." E " refers to IC50At 2 μMs and
Glutamine enzyme inhibitor between 10 μMs." N/A " refers to wherein not obtain IC50Compound.
Table 2
Embodiment 1
6,6'-(hexamethylene-1,3-diyl) double (pyridazine-3-alcohol) (I-5)
Step A:N1, N3-dimethoxy-N1, N3-dimethyl cyclohexane-1,3-diformamide (I-2):
100mL SOCl by stirring2In hexamethylene-1, (20g, 0.12mol, 2:1 are cis: trans mixing for 3-dicarboxylic acids
Thing) solution is heated to refluxing overnight.Concentrated, and with in the next step, it is not necessary to it is further purified.
At 0 DEG C, to CH2Cl2In N, O-dimethyl hydroxyl amine hydrochlorate (34g, 0.36mol) dropping DIPEA (45g,
CH 0.36mol) and subsequently2Cl2In hexamethylene-1,3-dicarbapentaborane dichloro made above.Mixture is at room temperature stirred
Mix overnight.With saturated NaHCO3Aqueous solution quencher.Organic layer is washed with saline, and through Na2SO4It is dried.Evaporated and passed through
Purification by flash chromatography, to obtain title compound I-2 (13g, 43%).
1H NMR(400MHz,CDCl3) cis δ: 3.68 (s, 6H), 3.14 (s, 6H), 2.74 (t, J=11.4Hz, 2H),
1.94 1.64 (m, 5H), 1.55 1.31 (m, 3H). trans δ: 3.71 (s, 6H), 3.24-3.35 (m, 2H), 3.19 (s, 6H),
1.84 (t, J=5.8Hz, 2H), 1.67 (m, 6H).
Step B:1,1'-(hexamethylene-1,3-diyl) diethyl ketone (I-3):
At-60 DEG C, N1, the N3-dimethoxy-N1 in the THF of stirring, N3-dimethyl cyclohexane-1,3-bis-formyl
Amine I-2 (5g, 0.03mol) dropping methyl-magnesium-bromide (3M, 30mL).Make mixture be warmed up to room temperature, and stir 3 hours.With full
The NH of sum4Cl aqueous solution quencher, uses CH2Cl2Extraction.Separate and evaporate organic layer to provide title compound I-3 (3g, 90%).
1H NMR(400MHz,CDCl3) cis δ: 2.37 (tt, J=12.1,3.0Hz, 1H), 2.15 (s, 6H), 2.07 (d,
J=12.1,1H), 1.98 1.91 (m, 2H), 1.43 1.32 (m, 3H), 1.28 1.21 (m, 3H). trans δ: 2.73 (m, 2H),
2.18 (s, 6H), 1.87 (t, J=5.8Hz, 2H), 1.68-1.78 (m, 4H), 1.48-1.57 (m, 2H).
Step C:2-(morpholino-4-) acetate (I-4):
10g 2-glyoxalic acid is added batch-wise to 100mL morpholine at 10 DEG C.The mixture of gained is stirred at 100 DEG C
5h.Then it is cooled to room temperature, then filters, filtrate is ground to obtain title compound I-4 with MTBE.
1H NMR(400MHz,DMSO-d6)δ:8.35(b,1H),3.79(b,4H),2.85(b,4H)。
Step D:6,6'-(hexamethylene-1,3-diyl) double (pyridazine-3-alcohol) (I-5):
20g 2-(morpholino-4-) acetate solution in 25mL MeOH adds 5g 1,1'-(-hexamethylene-1,3-
Diyl) diethyl ketone.The solution making gained refluxes 12h under argon gas.It is slowly added 3.0mL hydrazine hydrate to the solution of gained.Make institute
The mixture obtained is under argon gas in 70 DEG C of 6h that reflux;Then room temperature it is cooled to.Filter the precipitate occurred, wash with MeOH and do
Dry, to provide 4g cis-6,6'-(hexamethylene-1,3-diyl) double (pyridazine-3-alcohol).By mother liquor concentrations, and pass through flash chromatography
Purification, to obtain the 6 of 1.5g, 6'-(hexamethylene-1,3-diyl) double (pyridazine-3-alcohol) (trans: cis=1.5:1).
1Cis δ: 12.77 (s, the 2H) of H NMR (400MHz, DMSO-d6), 7.46 (d, J=9.8Hz, 2H), 6.83 (d, J
=9.8Hz, 2H), 2.68 (dt, J=12.0,3.4Hz, 2H), 1.97 (d, J=13.2Hz, 1H), 1.91-1.85 (m, 3H),
1.54-1.48 (m, 2H), 1.34 (qd, J=13.2,3.4Hz, 1H). trans δ: 11.10 (b.s., 2H), 7.26 (d, J=
9.6Hz, 2H), 6.96 (d, J=9.6Hz, 2H), 3.10 (quintet, J=5.8Hz, 2H), 2.09 (t, J=5.8Hz, 2H),
1.82-1.74 (m, 4H), 1.59 (m, 2H) .LC-MS:m/z (M+H)=273.2.
Embodiment 2
N, N'-(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) double (2-(pyridine-2-
Base) acetamide) (20)
Step A:(1R, 3S) double (the 6-chlorine pyridazine-3-base) hexamethylene (I-6) of-1,3-
By stirring in 2mL POCl3In 6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-3-alcohol)
(100mg, 0.37mmol) solution is heated to 80 DEG C 10 minutes.Then evaporated, and used frozen water quencher.Alkalize with 2N NaOH
Water layer, and use CH2Cl2Extraction.Organic layer is washed with saline, and through Na2SO4It is dried.Evaporated, and with quick post (PE:EA
=2:1 to 1:1) purification, to obtain desired product (30mg, 26%).
1H NMR(400MHz,CDCl3) δ: 7.45-7.54 (d, J=8.9Hz, 2H), 7.36-7.44 (d, J=8.6Hz,
2H), 3.24 (t, J=10.7Hz, 2H), 2.31 (d, J=12.6Hz, 1H), 2.14 (d, J=5.9Hz, 3H), 1.98-2.11
(q, J=12Hz, 1H), 1.67-1.75 (m, 3H).LC-MS:m/z (M+H)=309.0
Step B:N, N'-(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) double (2-(pyrroles
Pyridine-2-base) acetamide) (20)
Double (the 6-chlorine pyridazine-3-base) hexamethylene of (1R, 3S)-1,3-in the 1mL dioxane that will stir (50mg,
0.16mmol)、Cs2CO3(210mg,0.64mmol)、Pd2(dba)3Double diphenylphosphine-the 9,9-of (15mg, 0.016mmol), 4,5-
Dimethyl xanthene (xantphos) (14mg, 0.024mmol) solution was in 100 DEG C of microwave heatings 1 hour.Cooling reaction mixing
Thing, then filtration over celite pad, wash with dioxane.Evaporation solvent, by quick post and preparation HPLC purification subsequently
Residue, to obtain desired product (15mg, 18%).
1H NMR(400MHz,CDCl3) δ: 8.69 (d, J=4.3Hz, 2H), 8.47 (d, J=9.1Hz, 2H), 7.73 (td,
J=7.7,1.5Hz, 2H), 7.37 (d, J=9.1Hz, 2H), 7.33 (d, J=7.8Hz, 2H), 7.25-7.31 (m, 2H), 4.06
(s, 4H), 3.14 (t, J=7.2Hz, 2H), 2.26 (d, J=12.1Hz, 1H), 2.09 (d, J=8.9Hz, 3H), 1.84-2.01
(q, J=12Hz, 1H), 1.57-1.74 (m, 3H).LC-MS:m/z (M+H)=509.6.
N, N'-(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) double (2-phenylacetyls
Amine) (10)
Program is identical with the program of embodiment 2 step B.
1H NMR(400MHz,CDCl3) δ: 9.91 (s, 2H), 8.46 (d, J=9.4Hz, 2H), 7.37-7.39 (m, 6H),
7.31-7.34 (m, 4H), 7.28-7.31 (m, 2H), 3.96 (s, 4H), 3.09 (t, J=11.8Hz, 2H), 2.21 (d, J=
12.1Hz,1H),2.05(m,3H),1.87-1.97(m,1H),1.50-1.70(m,3H).LC-MS:m/z (M+H)=507.2
N, N'-(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) dipropyl acidamide) (152)
Program is identical with the program of embodiment 2 step B.
1H NMR(400MHz,CDCl3) δ: 8.58 (d, J=8.9Hz, 2H), 7.53 (d, J=9.1Hz, 2H), 3.16 (m,
2H), 2.63 (q, J=7.3Hz, 4H), 2.27 (d, J=8.6Hz, 1H), 2.13 (m, 3H), 1.99 (m, 1H), 1.69 (m, 3H),
(1.25-1.31 t, J=7.3Hz, 6H).LC-MS:m/z (M+H)=383.4
N, N'-(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) two butyramides) (37)
Program is identical with the program of embodiment 2 step B.
1H NMR(400MHz,CDCl3) δ: 10.41 (s, 2H), 8.53 (d, J=9.2Hz, 2H), 7.42 (d, J=9.3Hz,
2H), 3.12 (m, 2H), 2.66 (t, J=7.5Hz, 4H), 2.30 (d, J=12.8Hz, 1H), 2.12 (m, 3H), 1.95 (q, J=
12.5Hz, 1H), 1.77 (sextet, J=7.4Hz, 4H), 1.69 (m, 3H), 1.00 (t, J=7.4Hz, 6H).LC-MS:m/z
(M+H)=411.4
N, N'-(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) double (2-methyl propionyl
Amine) (98)
Program is identical with the program of embodiment 2 step B.
1H NMR(400MHz,CDCl3) δ: 9.64 (s, 2H), 8.50 (d, J=9.2Hz, 2H), 7.42 (d, J=9.2Hz,
2H), 3.14 (t, J=11.5Hz, 2H), 2.93 (septet, J=6.5Hz, 2H), 2.30 (d, J=12.4Hz, 1H), 2.12
(m, 3H), 1.96 (q, J=11.8Hz, 1H), 1.71 (m, 3H), 1.28 (d, J=6.5Hz, 12H).
Embodiment 3
N, N'-(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) diacetayl amide) (99)
Step A:(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) diamino acid hexichol
Methyl ester (176)
Program is identical with the program of embodiment 2.
1H NMR(400MHz,CDCl3) δ: 8.22 (d, J=8.9Hz, 4H), 7.36-7.46 (m, 10H), 5.26 (s, 4H),
3.14 (t, J=11.8Hz, 2H), 2.26 (d, J=14.8Hz, 1H), 2.10 (m, 3H), 1.89-2.05 (m, 1H), 1.56-
1.76(m,3H).LC-MS:m/z (M+H)=539.2
Step B:6,6'-((1R, 3S)-hexamethylene-1,3-diyl) two pyridazine-3-amine (I-7)
At room temperature, by double for 6'-((1R, 3S) hexamethylene-1,3 diyls) (pyridazine 6,3-diyl) diamino acid benzene methyl
(20mg, 0.037mmol) and 10mg 20%Pd (OH)2/ carbon suspension in 2mL MeOH is at H2Lower stirring 1.5h.Make reaction
Mixture filtration over celite pad, and wash with MeOH.Evaporation filtrate, and by preparation HPLC purification, obtain desired product
(7mg)。
1H NMR(400MHz,DMSO-d6) δ: 7.19 (d, J=9.1Hz, 2H), 6.71 (d, J=9.1Hz, 2H), 6.11
(s, 4H), 2.85 (t, J=11.7Hz, 2H), 1.93 (d, J=10.2Hz, 1H), 1.86 (m, 3H), 1.71 (m, 2H), 1.39-
1.62(m,4H).LC-MS:m/z (M+H)=271.1
Step C:N, N'-(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) diacetayl amide
(99)
By 6,6'-((1R, 3S)-hexamethylene-1,3-diyl) two pyridazine-3-amine (40mg, 0.145mmol), acetic acid
(0.05mL, 0.45mmol), HATU (171.1mg, 0.45mmol) and N-ethyl-N-iospropyl acrylate-2-amine (62mg,
0.48mmol) solution in N,N-dimethylformamide (5mL) is heated to 50 DEG C overnight.Pour the mixture into water (20mL)
In, precipitate is collected by filtration.By preparation TLC (ethyl acetate: methanol=10:1) pure solid, obtain desired product
(7mg)。
1H NMR(400MHz,DMSO-d6) δ: 11.03 (s, 2H), 8.24 (d, J=9.1Hz, 2H), 7.67 (d, J=
9.4Hz, 2H), 3.09 (t, J=11.8Hz, 2H), 2.13 (s, 6H), 2.21 (d, J=12.1Hz, 1H), 2.05 (m, 3H),
1.87-1.97(m,1H),1.50-1.70(m,3H).LC-MS:m/z (M+H)=355.2
N, N'-(6,6'-((1R, 3S)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) double (2-(3-(fluoroforms
Epoxide) phenyl) acetamide (180)
Program is identical with the program of step C of embodiment 3.
1H NMR(400MHz,CDCl3) δ: 11.68 (s, 2H), 8.50 (d, J=9.4Hz, 2H), 7.25-7.39 (m, 8H),
7.04-7.14 (m, 2H), 4.17 (s, 4H), 3.07 (t, J=11.8Hz, 2H), 2.23 (d, J=12.6Hz, 1H), 2.04 (m,
3H),1.85(m,1H),1.43-1.68(m,3H).LC-MS:m/z (M+H)=675.2.
Embodiment 4
Trans-(raceme)-N, N'-(6,6'-(hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) double (2-(pyrroles
Pyridine-2-base) acetamide) (14)
Step A:6,6'-(trans)-hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl) double (fluoroform sulphonates)
(I-8)
At 0 DEG C, to the 6 of stirring, and 6'-(hexamethylene-1,3-diyl) double (pyridazine-3-alcohol) (400mg, 1.5mmol, instead
Formula: cis=1.5:1) at 5mL CH2Cl2In solution add DIPEA (570mg, 4.5mmol), then add Tf2O
(846mg,3mmol).Make mixture be warmed up to room temperature, stir 3 hours.With saturated NaHCO3Aqueous solution quencher, uses CH2Cl2Extraction
Take.Separate organic layer, wash organic layer with saline, and through Na2SO4It is dried.Concentrated, and by quick post (PE:EA=2:1
To 1:1) purification, to obtain desired trans product (350mg, 45%).
1H NMR(400MHz,CDCl3) δ: 7.71 (d, J=8.9Hz, 2H), 7.40 (d, J=8.9Hz, 2H), 3.62 (q, J
=5.8Hz, 2H), 2.56 (t, J=5.8Hz, 2H), 2.03-2.14 (m, 4H), 1.74 (t, J=5.8Hz, 2H).LC-MS:m/z
(M+H)=537.0
Step B: anti-form-1, double (the 6-bromine pyridazine-3-base) hexamethylene (I-9) of 3-
6,6'-(trans)-hexamethylene-1,3-diyl to stirring) double (pyridazine-6,3-diyl) double (fluoroform sulphonates)
(350mg, 0.65mmol) is at 5mL CH3Solution in CN adds LiBr (280mg, 3.3mmol), be followed by HBr (0.32mL,
1.9mmol, in AcOH solution 33%).Heat the mixture to reflux 3 hours.Then concentrated, pure by quick post
Change, to obtain the product (135mg, 52%) of white solid.
1H NMR(400MHz,CDCl3) δ: 7.62-7.74 (d, J=8.9Hz, 2H), 7.39-7.48 (d, J=8.9Hz,
2H), 3.56 (q, J=5.8Hz, 2H), 2.52 (t, J=5.8Hz, 2H), 1.98-2.17 (m, 4H), 1.65-1.82 (m, 2H).
LC-MS:m/z (M+H)=397.0
Step C: trans-(raceme)-N, N'-(6,6'-(hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) is double
(2-(pyridine-2-base) acetamide) (14)
By double for (1R, 3S)-1,3-(6-chlorine pyridazine-3-base) hexamethylene (40mg, 0.1mmol), Cs2CO3(98mg,
0.3mmol)、Pd2(dba)3Double diphenylphosphine-9,9-dimethyl the xanthene of (14mg, 0.015mmol) and 4,5-(12mg,
0.02mmol) mixture in 2mL dioxane was in 110 DEG C of microwave heatings 1.5 hours.Make the mixture filtration over celite of cooling
Pad, and wash with dioxane.Then concentrate eluant, by preparation HPLC purification, to provide desired product (9mg).
1H NMR(400MHz,CDCl3) δ: 8.70 (d, J=4.4Hz, 2H), 8.41 (d, J=9.2Hz, 2H), 7.73 (td,
J=7.6,1.2Hz, 2H), 7.43 (d, J=9.2Hz, 2H), 7.27-7.34 (m, 4H), 4.03 (s, 4H), 3.39 (quintet, J
=5.6Hz, 2H), 2.44 (t, J=5.6Hz, 2H), 2.05 (m, 2H), 1.87-1.90 (m, 4H), 1.70 (m, 2H).LC-MS:
M/z (M+H)=509.6
Trans-(raceme)-N, N'-(6,6'-(hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) diacetayl amide
(41)
Program is identical with the program of step C of embodiment 4.
1H NMR (400MHz, DMSO-d6) δ: 8.19-8.26 (d, J=9.4Hz, 2H), 7.62-7.71 (d, J=
9.4Hz, 2H), 3.23-3.31 (quintet, J=5.8Hz, 2H), 2.31 (t, J=5.8Hz, 2H), 2.15 (s, 6H), 1.99
(m, 2H), 1.83-1.90 (m, 2H), 1.64 (d, J=5.9Hz, 2H).LC-MS:m/z (M+H)=355.5
Trans-(raceme)-N, N'-(6,6'-(hexamethylene-1,3-diyl) double (pyridazine-6,3-diyl)) double (2-(4-
(trifluoromethoxy) phenyl) acetamide) (75)
Program is identical with the program of step C of embodiment 4.
1H NMR(400MHz,CDCl3) δ: 8.50 (d, J=8.1Hz, 2H), 7.34-7.48 (m, 6H), 7.18 (d, J=
8.1Hz, 4H), 4.03 (s, 4H), 3.36 (quintet, J=5.8Hz, 2H), 2.38 (t, J=5.8Hz, 2H), 1.95-2.00
(m,2H),1.83-1.91(m,2H),1.61-1.65(m,2H).LC-MS:m/z (M+H)=675.6
Embodiment 5
2-phenyl-N-(6-((1S, 3R)-3-(5-(2-phenylacetamido)-1,3,4-thiadiazoles-2-base) cyclohexyl)
Pyridazine-3-base) acetamide (291)
Step A: trans-(raceme)-3-(5-amido-1,3,4-thiadiazoles-2-base) cyclohexanecarboxylate (I-10)
By trans-3-(methoxycarbonyl) naphthenic acid (30g, 0.161mol) and thiosemicarbazides (18.2g, 0.2mol)
At POCl3(80mL) solution in is heated to 40 DEG C and continues 30min, then 60 DEG C of lasting 30min, and then 80 DEG C continue 3h.When
Consumption of raw materials is complete, enriched mixture, and residue 4N NaOH is neutralized to pH=8, then extracts by ethyl acetate (3 × 150ml)
Mixture.It is dried the organic layer of merging with anhydrous sodium sulfate, filters, concentrate, by the crude product of flash column gained to obtain
To desired product (12g, 30%).
1H NMR (400MHz, DMSO-d6) δ: 7.04 (s, 2H), 3.63 (s, 3H), 3.12 (dt, J=8.3,4.1Hz,
1H),2.68-2.83(m,1H),2.00-2.15(m,1H),1.71-1.94(m,3H),1.44-1.68(m,4H),LC-MS:m/z
(M+H)=242.5
Step B: trans-(raceme)-3-(5-(2-phenylacetamido) 1,3,4-thiadiazoles 2-yl) cyclohexane-carboxylic acid
Methyl ester (I-11)
At 0 DEG C, to trans-3-(5-amido-1,3,4-thiadiazoles-2-base) cyclohexanecarboxylate (6g,
0.024mol) at CH2Cl2(100mL) solution in adds triethylamine (4.85g, 0.048mol), is then slowly added 2-phenyl
Chloroacetic chloride (4.6g, 0.029mol).Stirring mixture 4h.Then pour the mixture in 100mL water, and extract by ethyl acetate
Take.It is dried organic layer with anhydrous sodium sulfate, filters, then concentrate to obtain yellow solid.This solid is ground by ethyl acetate, and
Filter, to obtain title compound (8.5g, 0.023mol).LC-MS:m/z (M+H)=360.5
Step C: trans-(raceme)-N-methoxy-. N-methyl-3-(5-(2-phenylacetamido) 1,3,4-thiadiazoles
2 bases) cyclohexane carboxamide (I-12)
To trans-3-(5-(2-phenylacetamido)-1,3,4-thiadiazoles-2-base) cyclohexanecarboxylate (8.5g,
0.023mol) at CH3OH/THF (V:V=3:1;Solution in 120mL) adds containing LiOH H2O (1.98g, 0.047mol)
Water (20ml).Stirring reactant mixture 3h, is concentrated in vacuo, and is extracted with ethyl acetate.Water layer 1M HCl is adjusted to pH
=6.Filter the precipitate being consequently formed and be dried, to obtain trans-3-(5-(2-phenylacetamido)-1,3,4-thiadiazoles
2-yl) naphthenic acid (6g, 0.017mol).
LC-MS:m/z (M+H)=389.5
By trans-3-(5-(2-phenylacetamido) 1,3,4-thiadiazoles 2 base) naphthenic acid (6g, 0.017mol),
N, O-dimethyl hydroxyl amine hydrochlorate (3.37g, 0.034mol), HATU (7.26g, 0.019mol) and N-ethyl-N-iospropyl
Acrylate-2-amine (6.87g, the 0.068mol) heated overnight at 50 DEG C of the solution in 100mL DMF.Mixture is cooled down, then
Pour in 100mL water, then extract by ethyl acetate (3 × 100ml).The organic layer merged with saline washing, uses anhydrous slufuric acid
Sodium is dried, filters, concentrates, and by purification by flash chromatography, to obtain desired product (4.5g, 0.012mol).
LC-MS:m/z (M+H)=389.5
Step D: trans-N-(5-((1S, 3S)-3-acetyl group cyclohexyl)-1,3,4-thiadiazoles-2-base)-2-phenyl second
Amide (I-13)
At 0 DEG C, to trans-N-Methoxy-N-methyl-3-(5-(2-phenylacetamido) 1,3,4-thiadiazoles-2-
Base) cyclohexane carboxamide (4.5g, 0.012mol) solution interpolation CH in anhydrous THF (100mL)3MgBr(3.0M;
7.75mL).Then reactant mixture is stirred 2h, and by adding saturated NH4Cl aqueous solution quencher.With ethyl acetate (2 ×
100ml) extraction mixture;And with the organic layer of saline washing merging, be dried through anhydrous sodium sulfate, filter and concentrate, to obtain
Oily residue.By this residue of purification by flash chromatography to obtain product (3.0g, 73%).
1H NMR(400MHz,DMSO-d6)δ:12.69(s,1H),7.13-7.42(m,5H),3.80(s,2H),3.01-
3.20 (m, 1H), 2.58 (m, 1H), 2.20 (d, J=12.6Hz, 1H), 2.13 (s, 3H), 2.02 (d, J=12.1Hz, 1H),
1.83-1.96(m,2H),1.26-1.55(m,4H).LC-MS:m/z (M+H)=344.5
Step E: cis N-(5-(3-(6-hydroxypyridazin-3-base) cyclohexyl) 1,3,4-thiadiazoles-2-base) 2-phenyl second
Amide (I-14)
By 4-(carboxy-methylene) morpholine-4-(1.25g, 8.75mmol) and trans-N-(5 ((1S, 3S) 3-acetyl group
Cyclohexyl)-1,3,4-thiadiazoles-2-base)-2-phenyl-acetamides (1.5g, 4.37mmol) is at 50mL CH3Solution in OH adds
Heat 100 DEG C is overnight.Cooling mixture, then concentrates.Thus obtained crude product is directly used in next step.To being dissolved in 20mL
This crude product in n-BuOH adds N2H4·H2O (2ml), and heat the mixture to 130 DEG C of 4h.Cooling mixture is the denseest
Contracting, and by purification by flash chromatography, with obtain 6-((1S)-3-(5-amido-1,3,4-thiadiazoles-2-base) cyclohexyl) pyridazine-
3-alcohol (400mg crude product).
LC-MS:m/z (M+H)=278.5.
To 6-((1S)-3-(5-amino-1,3,4-thiadiazoles-2-base) cyclohexyl) pyridazine-3-alcohol (400mg crude product,
1.44mmol) at CH2Cl2In solution add triethylamine (291mg, 2.88mmol), be followed by 2-phenylacetyl chlorine (266mg,
1.73mmol).Reactant mixture is stirred at room temperature 1h.Enriched mixture, and by purification by flash chromatography residue to obtain
To title compound.
1H NMR (400MHz, DMSO-d6) δ: 12.79 (br.s., 1H), 12.68 (br.s., 1H), 7.48 (d, J=
9.7Hz, 1H), 7.32-7.35 (m, 2H), 7.22-7.31 (m, 3H), 6.83 (d, J=9.7Hz, 1H), 3.83 (s, 2H),
3.15-3.26 (m, 1H), 2.74 (t, J=12.1Hz, 1H), 2.19 (d, J=12.6Hz, 1H), 2.03-2.11 (m, 1H),
1.78-1.97(m,2H),1.36-1.61(m,4H);LC-MS:m/z (M+H)=396.5.
Step F: cis-N-(5-(3-(6-chlorine pyridazine-3-base) cyclohexyl)-1,3,4-thiadiazoles-2-base)-2-phenyl second
Amide (I-15)
By N-(5-(3-(6-hydroxypyridazin-3-base) cyclohexyl)-1,3,4-thiadiazoles-2-base) 2-phenyl-acetamides-
(260mg, 0.66mmol) is at POCl3(5mL) solution in is heated to 80 DEG C and continues 30min.Cooling mixture, then concentrates,
And with saturated Na2CO3Aqueous solution regulates to pH=8.Mixture is extracted by ethyl acetate (2 × 50ml).Merge with saline washing
Organic layer, be dried through anhydrous sodium sulfate, filter, concentrate, and by preparative TLC purification, to obtain title compound
(60mg, 22%).
1H NMR (400MHz, DMSO-d6) δ: 12.67 (br.s., 1H), 7.86 (d, J=8.9Hz, 1H), 7.80 (d, J
=9.1Hz, 1H), 7.30-7.37 (m, 4H), 7.27 (m, 1H), 3.80 (s, 2H), 3.27 (m, 1H), 3.15 (m, 1H), 2.27
(d, J=12.9Hz, 1H), 2.11 (m, 1H), 1.91-2.00 (m, 2H), 1.86 (q, J=12.9Hz, 1H), 1.50-1.60 (m,
3H).LC-MS:m/z (M+H)=414.5.
Step G:2-phenyl-N-(6-((1S, 3R)-3-(5-(2-phenylacetamido)-1,3,4-thiadiazoles-2-base) ring
Hexyl) pyridazine-3-base) acetamide (291)
Program is identical with the program of step B of embodiment 2.
1H NMR(400MHz,CDCl3) δ: 8.60 (d, J=9.1Hz, 1H), 7.49 (d, J=9.1Hz, 1H), 7.39-
7.43(m,4H),7.31-7.37(m,6H),4.03(s,2H),3.96(s,2H),3.29(m,1H),3.11(m,1H),2.45
(d, J=13.7Hz, 1H), 2.26 (m, 1H), 2.02-2.09 (m, 2H), 1.90 (q, J=13.7Hz, 1H), 1.54-1.72 (m,
3H).LC-MS:m/z (M+H)=513.5
Embodiment 6
N, N'-(6,6'-(Pentamethylene .-1,3-diyl) double (pyridazine-6,3-diyl)) double (2-(pyridine-2-base) acetamide)
(175)
Step A:N1, N3-dimethoxy-N1, N3-dimethylcyclopentane-1,3-diformamide (I-16):
By Pentamethylene .-1 of stirring, 3-dicarboxylic acids (20g, 0.13mol, 1:1 are cis: trans) is at 100mL SOCl2In
Solution is heated to refluxing overnight.Cooling mixture, concentrates, and with in the next step, it is not necessary to it is further purified.
At 0 DEG C, to CH2Cl2In N, O-dimethyl hydroxyl amine hydrochlorate (34g, 0.36mol) dropping DIPEA (45g,
CH 0.36mol) and subsequently2Cl2In Pentamethylene .-1,3-dicarbapentaborane dichloro made above.Mixture is at room temperature stirred
Mix overnight.Used saturated NaHCO3Aqueous solution processes, and then washs organic layer with saline, and through Na2SO4It is dried, and evaporation
Solvent.By purification by flash chromatography residue to provide desired product (20g, 65%).
1H NMR(400MHz,CDCl3) cis δ: 3.68 (s, 6H), 3.17 (s, 6H), 3.10 (m, 2H), 2.10 (m, 1H),
1.95 (m, 3H), 1.83 (m, 2H). trans δ: 3.68 (s, 6H), 3.32 (m, 2H), 3.17 (s, 6H), 2.07 (t, J=8Hz,
2H),2.00(m,2H),1.79(m,2H).LC-MS:m/z (M+H)=245.2
Step B:1,1'-(Pentamethylene .-1,3-diyl) diethyl ketone (I-17)
At-60 DEG C, to stirring N1, N3-dimethoxy-N1, N3-dimethyl cyclohexane-1,3-diformamide (5g,
0.02mol) dropping methyl-magnesium-bromide of the solution in THF (3M, 20mL).Make mixture be warmed up to room temperature, and stir 3 hours.
With saturated NH4Cl aqueous solution processes, and then uses CH2Cl2Extraction.Be dried and evaporate organic layer, with obtain desired product (3g,
93%).
1H NMR(400MHz,CDCl3) cis δ: 2.91 (m, 2H), 2.17 (s, 6H), 2.07 (m, 1H), 1.92 (m, 1H),
1.86-1.88 (m, 4H). trans δ: 3.00 (quintet, J=7.6Hz, 2H), 2.17 (s, 6H), 2.01 (t, J=7.8Hz,
2H),1.89(m,2H),1.75(m,2H)。
Step C:4,4'-(Pentamethylene .-1,3-diyl) double (2-morpholino-4-ketobutyric acid) (I-18)
To the 2-(morpholino-4-) acetate (15g) solution in MeOH (25mL) add 1,1'-(-Pentamethylene .-1,
3-diyl) diethyl ketone (3g).Reflux under argon gas 12h by the solution of gained.Then concentrated, with CH2Cl2Dissolve, and filter
To obtain title compound.It can use without being further purified.
LC-MS:m/z (M+H)=441.2
Step D:6,6'-(Pentamethylene .-1,3-diyl) double (pyridazine-3-alcohol) (I-19):
At room temperature, to the 4 of stirring, 4'-(Pentamethylene .-1,3-diyl) double (2-morpholino-4-ketobutyric acid) (8.7g,
0.02mol) solution in n-BuOH (50mL) adds hydrazine hydrate (1.0mL).The mixture making gained refluxes at 140 DEG C
12h, then cools down and concentrates.By purification by flash chromatography residue with obtain desired compound (trans: cis=1:
1%).
Cis δ: 12.77 (s, the 2H) of 1H NMR (400MHz, DMSO-d6), 7.21 (d, J=9.8Hz, 2H), 6.95 (d, J
=9.8Hz, 2H), 3.22 (m, 2H), 2.38 (dt, J=12.8,7.6Hz, 1H), 2.13 (m, 1H), 1.86-1.88 (m, 4H).
Trans δ: 12.77 (br.s., 2H), 7.26 (d, J=9.6Hz, 2H), 6.96 (d, J=9.6Hz, 2H), 3.30 (quintet, J=
7.4Hz, 2H), 2.20 (t, J=8.0Hz, 2H), 2.15 (m, 2H), 1.85 (m, 2H).LC-MS:m/z (M+H)=259.2
Double (the 6-chlorine pyridazine-3-base) Pentamethylene. (I-20) of step E:1,3-
By the 6,6'-(Pentamethylene .-1,3-diyl) double (pyridazine-3-alcohol) (1g, 0.38mmol) of stirring at POCl3(5mL)
In solution be heated to 80 DEG C continue 30 minutes.Cooling mixture, then concentrates, and treats with frozen water.With in 2N NaOH and water
Layer, and use CH2Cl2Extraction.Organic layer is washed with saline, and through Na2SO4It is dried.Remove solvent, and via purification by flash chromatography
Residue, to provide desired product (600mg, 50%).
1H NMR (400MHz, DMSO-d6) cis δ: 7.57 (d, J=8.9Hz, 2H), 7.48 (d, J=8.9Hz, 2H),
3.73 (m, 2H), 2.72 (dt, J=13.0,7.6Hz, 1H), 2.31-2.43 (m, 3H), 2.16 (m, 2H). trans δ: 7.47 (d,
J=8.9Hz, 2H), 7.40 (d, J=8.9Hz, 2H), 3.76 (quintet, J=7.8Hz, 2H), 2.54 (t, J=7.9Hz,
2H),2.43(m,2H),2.11(m,2H).LC-MS:m/z (M+H)=295.0
Step F:N, N'-(6,6'-(Pentamethylene .-1,3-diyl) double (pyridazine-6,3-diyl)) double (2-(pyridine-2-base)
Acetamide) (175)
By double for (1R, 3S)-1,3-of stirring (6-chlorine pyridazine-3-base) Pentamethylene. (50mg, 0.16mmol), Cs2CO3
(210mg,0.64mmol)、Pd2(dba)3Double diphenylphosphine-9,9-dimethyl the xanthene of (15mg, 0.016mmol), 4,5-
(14mg, 0.024mmol) solution in dioxane was in 100 DEG C of microwave heatings 1 hour.It is cooled to, then filtration over celite
Pad, and wash with dioxane.Concentrated filtrate, and by flash chromatography and preparation HPLC purification subsequently, to provide desired
Product (15mg, 18%, trans: cis=3:4).
1H NMR(400MHz,CDCl3) cis δ: 8.67 (d, J=4.6Hz, 2H), 8.38 (dd, J=9.1,7.0Hz,
2H), 7.73 (td, J=7.7,1.6Hz, 2H), 7.45 (d, J=9.2Hz, 2H), 7.26-7.29 (m, 4H), 3.96 (s, 4H),
3.60 (m, 2H), 2.61 (dt, J=12.4,6.0Hz, 1H), 2.20-2.42 (m, 3H), 2.10 (m, 2H). trans δ: 8.67 (d,
J=4.6Hz, 2H), 8.38 (dd, J=9.1,7.0Hz, 2H), 7.73 (td, J=7.7,1.6Hz, 2H), 7.35 (d, J=
9.2Hz, 2H), 7.26-7.29 (m, 4H), 3.96 (s, 4H), 3.68 (quintet, J=7.6Hz, 2H), 2.37 (t, J=
7.8Hz,2H),2.30(m,2H),2.07(m,2H).LC-MS:m/z (M+H)=494.5
Be thus described several aspects of several embodiment it should be understood that various change, modify and improve right
To be easy to perform in those skilled in the art.These change, modify and improve and be intended to as a part disclosed in this, and
It is intended to be within the spirit and scope of the present invention.Therefore, aforesaid explanation and graphic being merely possible to are illustrated.
Claims (20)
1. the compound of a formula (I) or its pharmaceutically acceptable salt:
Wherein
X is the C being optionally substituted3-C7Cycloalkylidene;
Each W, Y and Z independently be-S-,-CH=,-CH=CH-,-CH=CR1-、-CR1=CR1-,-O-,-N=or-NH-,
Condition be at least one of W, Y and Z for-CH=,
Each W', Y' and Z' independently be-S-,-CH=,-CH=CH-,-CH=CR2-、-CR2=CR2-,-O-,-N=or-
NH-, condition is that at least one of W', Y' and Z' is for-CH=;Condition be one of W, Y and Z be-CH=CH-,-CH=CR1-
Or-CR1=CR1-, and
When W is-CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of Y and Z independently be-CH=or-N=;
When Y is-CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of W and Z independently be-CH=or-N=;
When Z is-CH=CH-,-CH=CR1-or-CR1=CR1In-time, then each of Y and W independently be-CH=or-N=;
Condition be two of W', Y' and Z' for CH=CH-,-CH=CR2-or-CR2=CR2-, and
When W' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, the most each Y' and Z' independently be-CH=or-N=;
When Y' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, then each of W' and Z' independently be-CH=or-N
=;
When Z' is-CH=CH-,-CH=CR2-or-CR2=CR2In-time, then each of Y' and W' independently be-CH=or-N
=;
Each R1And R2Independently be-NH2、-N(R3)-C(O)-R4、-C(O)-N(R3)-R4、-N(R3)-C(O)-O-R4、-N(R3)-
C(O)-N(R3)-R4Or-N (R3)-C(O)-SR4;
Each R3Independently be hydrogen, C1-6Alkyl or aryl;
Each R4Independently be C1-6Alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloalkyl, cycloalkyl-alkyl, heterocycle alkane
Base or heterocyclic radical, each of which R occurred by 0 to 3 time5Replace;
Each R5Independently be C1-6Alkyl, C1-6Alkoxyl ,-O-C1-6Alkylidene C1-6Alkoxyl, C1-6Thio alkoxy, C1-6Halogen
Substituted alkyl, C3-7Cycloalkyl, C3-7Cycloalkyl-alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloheteroalkylalkyl, heterocyclic radical,
Cyano group, halogen, oxo ,-OH ,-OCF3、-OCHF2、-SO2-C1-6Alkyl ,-NO2、-N(R7)-C(O)-C1-6Alkyl ,-C (O) N
(R7)2、-N(R7)S(O)1-2-C1-6Alkyl ,-S (O)2N(R7)2、-N(R7)2、-C1-6Alkylidene-N (R7)2, wherein said alkyl,
C1-6Alkoxyl ,-O-C1-6Alkylidene C1-6Alkoxyl, C1-6Thio alkoxy, C1-6Haloalkyl, C3-7Cycloalkyl, C3-7Cycloalkyl
Alkyl, aryl, heteroaryl, aralkyl, heteroarylalkyl, cycloheteroalkylalkyl, heterocyclic radical ,-SO2-C1-6Alkyl ,-NO2、-N(R7)-C
(O)-C1-6Alkyl ,-C (O) N (R7)2、-N(R7)S(O)1-2-C1-6Alkyl ,-S (O)2N(R7)2、-N(R7)2, or-C1-6Alkylidene-N
(R7)2The R occurred by 0 to 3 time8Optionally replace;Or two R closed on5Part, atom in connection shape altogether
Become cycloalkyl or heterocyclic radical;
Each R6Independently be hydrogen, fluorine, C1-6Alkyl ,-OH ,-NH2、-NH(CH3)、-N(CH3)2, or C1-6Alkoxyl;
Each R7Independently be hydrogen or C1-6Alkyl;
Each R8Independently be halogen, C1-6Alkyl, C1-6Haloalkyl ,-OH ,-N (R7)2, or C1-6Alkoxyl ,-O-C1-6Alkylene
Base C1-6Alkoxyl, CN, NO2、-N(R7)-C(O)-C1-6Alkyl ,-C (O) N (R7)2、-N(R7)S(O)1-2C1-6Alkyl or-S (O)2N(R7)2;
M is 0,1 or 2;
N is 0,1 or 2;
O is 1,2 or 3;And
P is 1,2 or 3.
Compound the most according to claim 1, wherein W be-CH=CH-, Y be-N=, Z for-N=, W' for-S-, Y' for-
N=and Z' is-N=.
Compound the most according to claim 1, wherein o is 1 and p to be 1.
Compound the most according to claim 1, wherein m is 0 and n to be 0.
Compound the most according to claim 1, wherein n is 1 and m to be 1.
Compound the most according to claim 5, the most each R6It is all hydrogen.
Compound the most according to claim 1, wherein R1And R2Identical.
Compound the most according to claim 1, wherein R1And R2Different.
Compound the most according to claim 1, wherein R1And R2It is respectively-N (R3)-C(O)-R4, the most each R3For hydrogen and
Each R4For aralkyl or heteroarylalkyl, each of which R occurred by 0 to 3 time5Replace.
Compound the most according to claim 1, wherein said compound is the compound of formula (II):
11. compounds according to claim 10, wherein said compound is the compound of formula (IIa):
12. compounds according to claim 1, wherein said compound is the compound of formula (IIb):
13. compounds according to claim 1, wherein said compound be the compound of formula (IV) and q be 0,1,2,3 or
4:
14. compounds according to claim 1, wherein said compound is the compound of formula (IVa) and q is 0,1,2,3
Or 4:
15. compounds according to claim 1, wherein said compound is the compound of formula (IVb) and q is 0,1,2,3
Or 4:
16. compounds according to claim 1, wherein said compound is the compound of formula (IVc) and q is 0,1,2,3
Or 4:
The method of the compound of 17. 1 kinds of formulas I
It includes making
Reaction, wherein G is leaving group.
18. 1 kinds of pharmaceutical compositions, its compound comprising formula (I) or its pharmaceutically acceptable salt.
19. 1 kinds of methods treating cancer, described method includes using according to claim 1 to experimenter in need
Compound or compositions according to claim 18.
20. methods according to claim 19, wherein said cancer is selected from being characterized as following cancer: i) and reference standard
Compare low-level CAM 120/80 expression, ii) high-caliber Vimentin or iii compared with reference standard) low
Level or drop low-level carboxylase expression of enzymes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNPCT/CN2014/073812 | 2014-03-21 | ||
CN2014073812 | 2014-03-21 | ||
PCT/US2015/021781 WO2015143340A1 (en) | 2014-03-21 | 2015-03-20 | Compounds and their methods of use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106231900A true CN106231900A (en) | 2016-12-14 |
CN106231900B CN106231900B (en) | 2019-05-28 |
Family
ID=54145391
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201580020934.4A Expired - Fee Related CN106231900B (en) | 2014-03-21 | 2015-03-20 | Compound and its application method |
Country Status (14)
Country | Link |
---|---|
US (1) | US10000479B2 (en) |
EP (1) | EP3119199B1 (en) |
JP (2) | JP6602364B2 (en) |
KR (1) | KR20160127149A (en) |
CN (1) | CN106231900B (en) |
AU (1) | AU2015231053B2 (en) |
BR (1) | BR112016021620A2 (en) |
CA (1) | CA2943339A1 (en) |
EA (1) | EA201691896A1 (en) |
IL (1) | IL247921A0 (en) |
MX (1) | MX2016012244A (en) |
PH (1) | PH12016501838A1 (en) |
WO (1) | WO2015143340A1 (en) |
ZA (1) | ZA201606450B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110746416A (en) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | Glutaminase GLS1 inhibitor containing triazole structure or pharmaceutically acceptable salt thereof, and preparation method and application thereof |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2922832B1 (en) | 2012-11-21 | 2019-10-09 | Agios Pharmaceuticals, Inc. | Glutaminase inhibitors and methods of use |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
PT3137460T (en) | 2014-04-30 | 2019-12-30 | Pfizer | Cycloalkyl-linked diheterocycle derivatives |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115698A1 (en) * | 2000-08-10 | 2002-08-22 | Newcomb Robert W. | Selective inhibition of glutaminase by bis-thiadiazoles |
WO2008048967A1 (en) * | 2006-10-16 | 2008-04-24 | University Of Rochester | Tripodal cyclohexane derivatives and their use as carbohydrate receptors |
WO2013078123A1 (en) * | 2011-11-21 | 2013-05-30 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2037257A1 (en) | 1970-07-28 | 1972-02-03 | Farbwerke Hoechst AG, vorm. Meister Lucius & Brüning, 6000 Frankfurt | Poly-(5-amino-1,3,4-thiadiazol-2-yl) derivs prepn - intermediates for drug and polymer prodn |
US4070400A (en) | 1975-10-16 | 1978-01-24 | Merck & Co., Inc. | Diphenyl polyamides having a cyclohexylene moiety |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4517288A (en) | 1981-01-23 | 1985-05-14 | American Hospital Supply Corp. | Solid phase system for ligand assay |
CA1291031C (en) | 1985-12-23 | 1991-10-22 | Nikolaas C.J. De Jaeger | Method for the detection of specific binding agents and their correspondingbindable substances |
US4843155A (en) | 1987-11-19 | 1989-06-27 | Piotr Chomczynski | Product and process for isolating RNA |
CA2155759A1 (en) | 1993-03-29 | 1994-10-13 | Bernd Janssen | 1-amino-3-phenoxy propane derivatives as modulators of multi-drug resistance |
US5895748A (en) | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
DE69923681T2 (en) | 1998-06-18 | 2006-01-12 | Bristol-Myers Squibb Co. | CARBON SUBSTITUTED AMINOTHIAZOLE AS INHIBITORS OF CYCLINE-DEPENDENT KINASES |
WO2000052204A2 (en) | 1999-02-22 | 2000-09-08 | Orntoft Torben F | Gene expression in bladder tumors |
AU2001249064A1 (en) | 2000-02-22 | 2001-09-03 | Mount Sinai School Of Medicine Of New York University | N-cadherin modulated migration, invasion, and metastasis |
US6974667B2 (en) | 2000-06-14 | 2005-12-13 | Gene Logic, Inc. | Gene expression profiles in liver cancer |
DK1388734T3 (en) | 2002-08-01 | 2004-05-03 | Mtm Lab Ag | Method for solution-based diagnosis |
WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
US20080182865A1 (en) | 2005-03-11 | 2008-07-31 | Witta Samir E | Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors |
DE602006016085D1 (en) | 2005-03-16 | 2010-09-23 | Genentech Inc | BIOLOGICAL MARKERS PREDICTIVE FOR THE APPLICATION OF CANCER TO INHIBITORS OF THE CINEMA OF THE RECEPTOR FOR EPIDERMAL GROWTH FACTOR |
CA2702462A1 (en) | 2007-11-19 | 2009-05-28 | Genentech, Inc. | Compositions and methods for inhibiting tumor progression |
JP2011516826A (en) | 2008-03-07 | 2011-05-26 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | Methods for identification of mesenchymal-like tumor cells or agents that inhibit this formation |
US20120190565A1 (en) | 2009-02-20 | 2012-07-26 | Pangea Biosciences, Inc. | Method Of Diagnosis Or Prognosis Of A Neoplasm Comprising Determining The Level Of Expression Of A Protein In Stromal Cells Adjacent To The Neoplasm |
WO2010111504A2 (en) | 2009-03-25 | 2010-09-30 | Cornell University | Inhibition of glutaminase c |
US20120142028A1 (en) | 2009-04-17 | 2012-06-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
JP5944385B2 (en) | 2010-06-23 | 2016-07-05 | ユニバーシティ オブ ルーイビル リサーチ ファウンデーション,インコーポレーテッド | Method for detecting cancer |
US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
UY33930A (en) | 2011-03-04 | 2012-10-31 | Novartis Ag | NEW QUINASE INHIBITORS |
CN102827073A (en) * | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | Therapeutically active compositions and application methods thereof |
KR20140138956A (en) | 2012-03-15 | 2014-12-04 | 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 | Combination therapies including inhibitors of the extracellular domain of e-cadherin |
EP2922832B1 (en) | 2012-11-21 | 2019-10-09 | Agios Pharmaceuticals, Inc. | Glutaminase inhibitors and methods of use |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
WO2014138391A1 (en) | 2013-03-06 | 2014-09-12 | The Johns Hopkins University | Targeting glutamine metabolism in brain tumors |
JP6783663B2 (en) * | 2014-01-06 | 2020-11-11 | ライゼン・ファーマシューティカルズ・エスアー | New glutaminase inhibitor |
-
2015
- 2015-03-20 EA EA201691896A patent/EA201691896A1/en unknown
- 2015-03-20 MX MX2016012244A patent/MX2016012244A/en unknown
- 2015-03-20 AU AU2015231053A patent/AU2015231053B2/en not_active Ceased
- 2015-03-20 EP EP15764391.7A patent/EP3119199B1/en active Active
- 2015-03-20 WO PCT/US2015/021781 patent/WO2015143340A1/en active Application Filing
- 2015-03-20 BR BR112016021620A patent/BR112016021620A2/en not_active Application Discontinuation
- 2015-03-20 KR KR1020167029269A patent/KR20160127149A/en unknown
- 2015-03-20 CA CA2943339A patent/CA2943339A1/en not_active Abandoned
- 2015-03-20 US US15/127,742 patent/US10000479B2/en active Active
- 2015-03-20 CN CN201580020934.4A patent/CN106231900B/en not_active Expired - Fee Related
- 2015-03-20 JP JP2017501134A patent/JP6602364B2/en not_active Expired - Fee Related
-
2016
- 2016-09-19 ZA ZA2016/06450A patent/ZA201606450B/en unknown
- 2016-09-19 IL IL247921A patent/IL247921A0/en unknown
- 2016-09-20 PH PH12016501838A patent/PH12016501838A1/en unknown
-
2019
- 2019-10-08 JP JP2019184947A patent/JP2020019807A/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020115698A1 (en) * | 2000-08-10 | 2002-08-22 | Newcomb Robert W. | Selective inhibition of glutaminase by bis-thiadiazoles |
WO2008048967A1 (en) * | 2006-10-16 | 2008-04-24 | University Of Rochester | Tripodal cyclohexane derivatives and their use as carbohydrate receptors |
WO2013078123A1 (en) * | 2011-11-21 | 2013-05-30 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110746416A (en) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | Glutaminase GLS1 inhibitor containing triazole structure or pharmaceutically acceptable salt thereof, and preparation method and application thereof |
WO2021042723A1 (en) * | 2019-09-05 | 2021-03-11 | 中国药科大学 | Glutaminase gls1 inhibitor containing triazole structure or pharmaceutically acceptable salt thereof, preparation method therefor, and application thereof |
Also Published As
Publication number | Publication date |
---|---|
US10000479B2 (en) | 2018-06-19 |
JP6602364B2 (en) | 2019-11-06 |
CN106231900B (en) | 2019-05-28 |
WO2015143340A1 (en) | 2015-09-24 |
CA2943339A1 (en) | 2015-09-24 |
AU2015231053A1 (en) | 2016-10-06 |
BR112016021620A2 (en) | 2018-07-10 |
JP2020019807A (en) | 2020-02-06 |
EP3119199A1 (en) | 2017-01-25 |
KR20160127149A (en) | 2016-11-02 |
ZA201606450B (en) | 2019-12-18 |
US20170137414A1 (en) | 2017-05-18 |
JP2017509703A (en) | 2017-04-06 |
EA201691896A1 (en) | 2017-01-30 |
PH12016501838A1 (en) | 2017-01-09 |
EP3119199B1 (en) | 2020-03-18 |
EP3119199A4 (en) | 2017-11-15 |
MX2016012244A (en) | 2017-05-08 |
IL247921A0 (en) | 2016-11-30 |
AU2015231053B2 (en) | 2019-04-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105263915B (en) | Glutamine enzyme inhibitor and application method | |
CN104936954B (en) | Compound and its application method | |
CN102448951B (en) | Therapeutic compositions and related methods of use | |
CN104817498B (en) | Therapeutic compound and composition | |
JP2015078232A (en) | Therapeutic compositions and related methods of use | |
JP5837091B2 (en) | Novel N- (4- (azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as modulators of pyruvate kinase M2 (PKM2) | |
CN109415361B (en) | Acrylic acid derivative, preparation method thereof and application thereof in medicine | |
CN109563060A (en) | IDO1 inhibitor and its preparation method and application | |
JP2020019807A (en) | Compounds and their methods of use | |
JP2019508496A (en) | TAF1 inhibitors for the treatment of cancer | |
CN105343073B (en) | A kind of compound that can be used as Wnt signal pathway activator and its preparation and application | |
WO2020179859A1 (en) | Pyrrolopyrazole derivative | |
CN105636943B (en) | The chromene derivative of inhibitor as TCR-Nck interaction |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210804 Address after: Fa Guoxuleineshi Patentee after: LES LABORATOIRES SERVIER Address before: Massachusetts, USA Patentee before: AGIOS PHARMACEUTICALS Inc. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190528 |